US20140206608A1 - Exendin-4 Derivatives - Google Patents

Exendin-4 Derivatives Download PDF

Info

Publication number: US20140206608A1
Authority: US; United States
Prior art keywords: carboxy; butyryl; ethoxy; amino acid; acid residue
Prior art date: 2012-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US14/135,756

Other languages

English (en)

Inventor

Torsten HAACK

Michael Wagner

Bernd Henkel

Siegfried Stengelin

Andreas EVERS

Martin Lorenz

Katrin LORENZ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi SA

Original Assignee

Sanofi SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-21

Filing date

2013-12-20

Publication date

2014-07-24

2013-12-20 Application filed by Sanofi SA filed Critical Sanofi SA

2014-05-13 Assigned to SANOFI reassignment SANOFI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EVERS, ANDREAS, HAACK, TORSTEN, HENKEL, BERND, LORENZ, KATRIN, LORENZ, MARTIN, STENGELIN, SIEGFRIED, WAGNER, MICHAEL

2014-07-24 Publication of US20140206608A1 publication Critical patent/US20140206608A1/en

Status Abandoned legal-status Critical Current

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

the present invention relates to exendin-4 peptide analogues which activate the glucagon-like peptide 1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP) receptor and optionally the glucagon receptor (GCG) and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
GLP-1 glucagon-like peptide 1
GIP glucose-dependent insulinotropic polypeptide
GCG glucagon receptor
Exendin-4 is a 39 amino acid peptide which is produced by the salivary glands of the Gila monster (Heloderma suspectum) (Eng J. et al., J. Biol. Chem., 267: 7402-05, 1992). Exendin-4 is an activator of the glucagon-like peptide-1 (GLP-1) receptor, whereas it shows only very low activation of the GIP receptor and does not activate the glucagon receptor (see Table 1).
GLP-1 glucagon-like peptide-1
Exendin-4 shares many of the glucoregulatory actions observed with GLP-1. Clinical and non-clinical studies have shown that exendin-4 has several beneficial antidiabetic properties including a glucose dependent enhancement in insulin synthesis and secretion, glucose dependent suppression of glucagon secretion, slowing down gastric emptying, reduction of food intake and body weight, and an increase in beta-cell mass and markers of beta cell function (Gentilella R et al., Diabetes Obes Metab., 11:544-56, 2009; Norris S L et al., Diabet Med., 26:837-46, 2009; Bunck M C et al., Diabetes Care., 34:2041-7, 2011).
exendin-4 is more resistant to cleavage by dipeptidyl peptidase-4 (DPP4) resulting in a longer half-life and duration of action in vivo (Eng J., Diabetes, 45 (Suppl 2):152A (abstract 554), 1996; Deacon C F, Horm Metab Res, 36: 761-5, 2004).
DPP4 dipeptidyl peptidase-4
Exendin-4 was also shown to be much more stable towards degradation by neutral endopeptidase (NEP), when compared to GLP-1, glucagon or oxyntomodulin (Druce M R et al., Endocrinology, 150(4), 1712-1721, 2009).
NEP neutral endopeptidase
exendin-4 is chemically labile due to methionine oxdiation in position 14 (Hargrove D M et al., Regul. Pept., 141: 113-9, 2007) as well as deamidation and isomerization of asparagine in position 28 (WO 2004/035623).
amino acid sequence of exendin-4 is shown as SEQ ID NO: 1:
amino acid sequence of GLP-1(7-36)-amide is shown as SEQ ID NO: 2:
Liraglutide is a marketed chemically modified GLP-1 analogue in which, among other modifications, a fatty acid is linked to a lysine in position 20 leading to a prolonged duration of action (Drucker D J et al, Nature Drug Disc. Rev. 9, 267-268, 2010; Buse, J B et al., Lancet, 374:39-47, 2009).
the amino acid sequence of Liraglutide is shown as SEQ ID NO: 3:
GIP glucose-dependent insulinotropic polypeptide
GIP and GLP-1 are the two gut enteroendocrine cell-derived hormones accounting for the incretin effect, which accounts for over 70% of the insulin response to an oral glucose challenge (Baggio L L, Drucker D J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157).
GIP's amino acid sequence is shown as SEQ ID NO: 4:
Glucagon is a 29-amino acid peptide which is released into the bloodstream when circulating glucose is low. Glucagon's amino acid sequence is shown in SEQ ID NO: 5:
hypoglycemia when blood glucose levels drop below normal, glucagon signals the liver to break down glycogen and release glucose, causing an increase of blood glucose levels to reach a normal level. Hypoglycemia is a common side effect of insulin treated patients with hyperglycemia (elevated blood glucose levels) due to diabetes. Thus, glucagon's most predominant role in glucose regulation is to counteract insulin action and maintain blood glucose levels.
GLP-1 receptor agonists such as GLP-1, Liraglutide and exendin-4
FPG and PPG fasting and postprandial glucose
GLP-1 and GIP receptors dual activation of the GLP-1 and GIP receptors, e.g. by combining the actions of GLP-1 and GIP in one preparation, leads to a therapeutic principle with significantly better reduction of blood glucose levels, increased insulin secretion and reduced body weight in mice with T2DM and obesity compared to the marketed GLP-1 agonist liraglutide (e.g. VA Gault et al., Clin Sci (Lond), 121, 107-117, 2011).
Native GLP-1 and GIP were proven in humans following co-infusion to interact in an additive manner with a significantly increased insulinotropic effect compared to GLP-1 alone (MA Nauck et al., J. Clin. Endocrinol. Metab., 76, 912-917, 1993).
Compounds of this invention are exendin-4 derivatives, which show agonistic activity at the GLP-1 and the GIP receptor and optionally the glucagon receptor and which have—among others—preferably the following modifications: Tyr at position 1 and Ile at position 12.
Peptides which bind and activate both the GIP and the GLP-1 receptor and optionally the glucagon receptor, and improve glycaemic control, suppress body weight gain and reduce food intake are described in patent applications WO 2011/119657 A1, WO 2012/138941 A1, WO 2010/011439 A2, WO 2010/148089 A1, WO 2011/094337 A1, WO 2012/088116 A2, the contents of which are herein incorporated by reference. These applications disclose that mixed agonists of the GLP-1 receptor, the GIP receptor and optionally the glucagon receptor can be designed as analogues of the native GIP or glucagon sequences.
Exendin-4 peptide analogues comprising leucine in position 10 and glutamine in position 13.
Krstenansky et al. show the importance of residues 10 to 13 of glucagon for its receptor interactions and activation of adenylate cyclase.
residues Tyr10 and Tyr13 are replaced by leucine in position 10 and glutamine, a non-aromatic polar amino acid, in position 13.
exendin-4 derivatives with potentially improved biophysical properties as solubility or aggregation behavior in solution.
the non-conservative replacement of an aromatic amino acid with a polar amino acid in position 13 of an exendin-4 analogue surprisingly leads to peptides with high activity on the GIP receptor and optionally on the glucagon receptor.
compounds of this invention are exendin-4 derivatives which show high activity on the GLP-1 receptor and the GIP receptor with only 4 to 6 amino acids replaced compared to exendin-4.
the replacement of the amino acids in position 1, 2, 12 and 14 in combination with the substitution with a fatty acid leads to exendin-4 derivatives which are potent GLP-1 receptor, GIP receptor and—optionally—glucagon receptor agonists and show potentially an improved enzymatic stability, for example versus trypsin, plasmin or ⁇ -chymotrypsin, leading to improved in vivo properties as half life and clearance, as shown in Examples 6 and 7 as well as in Tables 8 and 9.
exendin-4 analogs which potently activate the GLP-1 and the GIP receptor and optionally the glucagon receptor.
methionine at position 14 is replaced by an amino acid carrying an —NH 2 group in the side-chain, which is further substituted with a lipophilic side-chain (e.g. a fatty acid optionally combined with a linker).
the invention provides a peptidic compound having the formula (I):
the compounds of the invention are GLP-1 and GIP receptor agonists and optionally glucagon receptor agonists as determined by the observation that they are capable of stimulating intracellular cAMP formation.
In vitro potency determination in cellular assays of agonists is quantified by determining the concentrations that cause 50% activation of maximal response (EC 50 ) as described in Methods.
the invention therefore provides a peptidic compound having the formula (I):
the peptidic compound particularly with a lysine at position 14 which is further substituted with a lipophilic residue, exhibits a relative activity of at least 0.07%, preferably at least 0.1%, more preferably at least 0.14%, more preferably at least 0.35% and even more preferably at least 0.4% compared to that of GLP-1(7-36) at the GLP-1 receptor.
the peptidic compound particularly with a lysine at position 14 which is further substituted with a lipophilic residue, exhibits a relative activity of at least 0.1%, preferably at least 0.2%, more preferably at least 0.3%, more preferably at least 0.4% and even more preferably at least 0.5% compared to that of natural glucagon at the glucagon receptor.
the term “activity” as used herein preferably refers to the capability of a compound to activate the human GLP-1 receptor, the human GIP receptor and optionally the human glucagon receptor. More preferably the term “activity” as used herein refers to the capability of a compound to stimulate intracellular cAMP formation.
the term “relative activity” as used herein is understood to refer to the capability of a compound to activate a receptor in a certain ratio as compared to another receptor agonist or as compared to another receptor. The activation of the receptors by the agonists (e.g. by measuring the cAMP level) is determined as described herein, e.g. as described in the examples.
the compounds of the invention have an EC 50 for hGLP-1 receptor of 500 pM or less, preferably of 200 pM or less; more preferably of 150 pM or less, more preferably of 100 pM or less, more preferably of 90 pM or less, more preferably of 80 pM or less, more preferably of 70 pM or less, more preferably of 60 pM or less, more preferably of 50 pM or less, more preferably of 40 pM or less, more preferably of 30 pM or less, and more preferably of 20 pM or less.
the compounds of the invention have an EC 50 for hGIP receptor of 500 pM or less, preferably of 200 pM or less; more preferably of 150 pM or less, more preferably of 100 pM or less, more preferably of 90 pM or less, more preferably of 80 pM or less, more preferably of 70 pM or less, more preferably of 60 pM or less, more preferably of 50 pM or less, more preferably of 40 pM or less, more preferably of 30 pM or less, and more preferably of 20 pM or less.
the compounds of the invention have optionally an EC 50 for hGlucagon receptor of 500 pM or less, preferably of 200 pM or less; more preferably of 150 pM or less, more preferably of 100 pM or less, more preferably of 90 pM or less, more preferably of 80 pM or less, more preferably of 70 pM or less, more preferably of 60 pM or less, more preferably of 50 pM or less, more preferably of 40 pM or less, more preferably of 30 pM or less, and more preferably of 20 pM or less.
an EC 50 for hGlucagon receptor of 500 pM or less, preferably of 200 pM or less; more preferably of 150 pM or less, more preferably of 100 pM or less, more preferably of 90 pM or less, more preferably of 80 pM or less, more preferably of 70 pM or less, more preferably of 60 pM or less, more preferably of 50 pM or
the compounds of the invention have an EC 50 for hGLP-1 receptor of 500 pM or less, preferably of 200 pM or less; more preferably of 150 pM or less, more preferably of 100 pM or less, more preferably of 90 pM or less, more preferably of 80 pM or less, more preferably of 70 pM or less, more preferably of 60 pM or less, more preferably of 50 pM or less, more preferably of 40 pM or less, more preferably of 30 pM or less, and more preferably of 20 pM or less, and/or an EC 50 for hGIP receptor of 500 pM or less, preferably of 200 pM or less; more preferably of 150 pM or less, more preferably of 100 pM or less, more preferably of 90 pM or less, more preferably of 80 pM or less, more preferably of 70 pM or less, more preferably of 60 pM or less, more preferably of 50 p
the EC 50 for both receptors is 500 pM or less, more preferably 200 pM or less, more preferably 150 pM or less, more preferably 100 pM or less, more preferably 90 pM or less, more preferably 80 pM or less, more preferably 70 pM or less, more preferably 60 pM or less, more preferably 50 pM or less, more preferably 40 pM or less, more preferably 30 pM or less, more preferably 20 pM or less.
the EC 50 for all three receptors is 500 pM or less, more preferably 200 pM or less, more preferably 150 pM or less, more preferably 100 pM or less, more preferably 90 pM or less, more preferably 80 pM or less, more preferably 70 pM or less, more preferably 60 pM or less, more preferably 50 pM or less, more preferably 40 pM or less, more preferably 30 pM or less, more preferably 20 pM or less.
the EC 50 for hGLP-1 receptor, hGIP receptor and hGlucagon receptor may be determined as described in the Methods herein and as used to generate the results described in Example 5.
the compounds of the invention have the ability to reduce the intestinal passage, to increase the gastric content and/or to reduce the food intake of a patient. These activities of the compounds of the invention can be assessed in animal models known to the skilled person and also described herein in the Methods. The results of such experiments are described in Examples 11 and 12.
Preferred compounds of the invention may increase the gastric content of mice, preferably of female NMRI-mice, if administered as a single dose, preferably subcutaneous dose, of 0.02 mg/kg body weight by at least 25%, more preferably by at least 30%, more preferably by at least 40%, more preferably by at least 50%, more preferably by at least 60%, more preferably by at least 70%, more preferably by at least 80%.
this result is measured 1 h after administration of the respective compound and 30 mins after administration of a bolus, and/or reduces intestinal passage of mice, preferably of female NMRI-mice, if administered as a single dose, preferably subcutaneous dose, of 0.02 mg/kg body weight at least by 45%; more preferably by at least 50%, more preferably by at least 55%, more preferably by at least 60%, and more preferably at least 65%; and/or reduces food intake of mice, preferably of female NMRI-mice, over a period of 22 h, if administered as a single dose, preferably subcutaneous dose of 0.01 mg/kg body weight by at least 10%, more preferably 15%, and more preferably 20%.
the compounds of the invention have the ability to reduce blood glucose level, and/or to reduce HbA1c levels of a patient. These activities of the compounds of the invention can be assessed in animal models known to the skilled person and also described herein in the Methods. The results of such experiments are described in Examples 9 and 10.
Preferred compounds of the invention may reduce blood glucose level of mice, preferably in female leptin-receptor deficient diabetic db/db mice over a period of 24 h, if administered as a single dose, preferably subcutaneous dose, of 0.01 mg/kg body weight by at least 4 mmol/L; more preferably by at least 6 mmol/L, more preferably by at least 8 mmol/L. If the dose is increased to 0.1 mg/kg body weight a more pronounced reduction of blood glucose levels can be observed in mice over a period of 24 h, if administered as a single dose, preferably subcutaneous dose.
the compounds of the invention lead to a reduction by at least 7 mmol/L; more preferably by at least 9 mmol/L, more preferably by at least 11 mmol/L.
the compounds of the invention preferably reduce the increase of HbA1c levels of mice over a period of 4 weeks, if administered at a daily dose of 0.01 mg/kg to about the ignition value.
the compounds of the invention also have the ability to reduce body weight of a patient. These activities of the compounds of the invention can be assessed in animal models known to the skilled person and also described herein in the Methods and in Example 8.
peptidic compounds of the formula (I), particularly those with a lysine (or close analogs) at position 14 which is further substituted with a lipophilic residue showed very potent GLP-1 and GIP receptor activation; additionally in combination with amino acids like Gln in position 3 also very potent glucagon receptor activation can be provided.
compounds of the invention preferably have a high solubility at acidic and/or physiological pH values, e.g., at pH 4.5 and/or at pH 7.4 at 25° C., in another embodiment at least 0.5 mg/ml and in a particular embodiment at least 1.0 mg/ml.
compounds of the invention preferably have a high stability when stored in solution.
Preferred assay conditions for determining the stability is storage for 7 days at 25° C. in solution at pH 4.5 or pH 7.4. The remaining amount of peptide is determined by chromatographic analyses as described in Methods and Examples.
the remaining peptide amount is at least 80%, more preferably at least 85%, even more preferably at least 90% and even more preferably at least 95%.
the compounds of the present invention comprise a peptide moiety Z (formula II) which is a linear sequence of 39-40 amino carboxylic acids, particularly ⁇ -amino carboxylic acids linked by peptide, i.e. carboxamide, bonds.
position X14 represents an amino acid residue with a functionalized —NH 2 side chain group, such as functionalized Lys, Orn, Dab, or Dap, more preferably functionalized Lys and X40 is absent or represents Lys.
a functionalized —NH 2 side chain group such as functionalized Lys, Orn, Dab, or Dap, more preferably functionalized Lys and X40 is absent or represents Lys.
An amino acid residue with an —NH 2 side chain group may be functionalized in that at least one H atom of the —NH 2 side chain group is replaced by —C(O)—R 5 , —C(O)O—R 5 , —C(O)NH—R 5 , —S(O)2-R5 or R 5 , preferably by —C(O)—R 5 , wherein R 5 is a moiety comprising up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and/or P.
R 5 may comprise a lipophilic moiety, e.g. an acyclic linear or branched saturated hydrocarbon group, wherein R 5 particularly comprises an acyclic linear or branched (C 4 -C 30 ) saturated or unsaturated hydrocarbon group, and/or a cyclic saturated, unsaturated or aromatic group, particularly a mono-, bi-, or tricyclic group comprising 4 to 14 carbon atoms and 0, 1, or 2 heteroatoms selected from N, O, and S, e.g.
a lipophilic moiety e.g. an acyclic linear or branched saturated hydrocarbon group, wherein R 5 particularly comprises an acyclic linear or branched (C 4 -C 30 ) saturated or unsaturated hydrocarbon group, and/or a cyclic saturated, unsaturated or aromatic group, particularly a mono-, bi-, or tricyclic group comprising 4 to 14 carbon atoms and 0, 1, or 2 heteroatoms selected from N, O, and S, e.g.
cyclohexyl phenyl, biphenyl, chromanyl, phenanthrenyl or naphthyl, wherein the acyclic or cyclic group may be unsubstituted or substituted e.g. by halogen, —OH and/or CO 2 H.
R 5 may comprise a lipophilic moiety, e.g. an acyclic linear or branched (C 12 -C 22 ) saturated or unsaturated hydrocarbon group.
the lipophilic moiety may be attached to the —NH 2 side chain group by a linker in all stereoisomeric forms, e.g. a linker comprising one or more, e.g. 2, 3 or 4, amino acid linker groups such as ⁇ -aminobutyric acid (GABA), ⁇ -aminohexanoic acid ( ⁇ -Ahx), ⁇ -Glu and/or ⁇ -Ala.
the lipophilic moiety is attached to the —NH 2 side chain group by a linker.
the lipophilic moiety is directly attached to the —NH 2 side chain group.
amino acid linker groups are ( ⁇ -Ala) 1-4 , ( ⁇ -Glu) 1-4 , ( ⁇ -Ahx) 1-4 , or (GABA) 1-4 .
Preferred amino acid linker groups are 8-Ala, ⁇ -Glu, ⁇ -Ala- ⁇ -Ala and ⁇ -Glu- ⁇ -Glu.
—C(O)—R 5 groups are listed in the following Table 3, which are selected from the group consisting of (S)-4-Carboxy-4-hexadecanoylamino-butyryl-, (S)-4-Carboxy-4-octadecanoylamino-butyryl-, 4-Hexadecanoylamino-butyryl-, 4- ⁇ 3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino ⁇ -butyryl-, 4-octadecanoylamino-butyryl-, 4-((Z)-octadec-9-enoylamino)-butyryl-, 6-[(4,4-Diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl-, Hexadecan
stereoisomers particularly enantiomers of these groups, either S- or R-enantiomers.
R in Table 3 is intended to mean the attachment site of —C(O)—R 5 at the peptide back bone, i.e. particularly the ⁇ -amino group of Lys.
the invention relates to peptidic compounds of Formula (I) as defined above, wherein X14 represents an amino acid residue selected from Lys, Orn, Dab and Dap, wherein the —NH 2 side chain group is functionalized by —C(O)—R 5 , X40 represents an amino acid residue selected from Lys, Orn, Dab and Dap, wherein the —NH 2 side chain group can be functionalized by —C(O)—R 5 , and R 5 is a lipophilic moiety selected from an acyclic linear or branched (C 4 -C 30 ) saturated or unsaturated hydrocarbon group, and/or a cyclic saturated, unsaturated or aromatic group, wherein the lipophilic moiety may be attached to the —NH 2 side chain group by a linker selected from ( ⁇ -Ala) 1-4 , ( ⁇ -Glu) 1-4 , ( ⁇ -Ahx) 1-4 , or (GABA) 1-4 in all stereoisomeric forms.
a linker selected from (
X14 represents an amino acid residue with a functionalized —NH 2 side chain group, such as functionalized Lys, Orn, Dab or Dap, wherein at least one H atom of the —NH 2 side chain group is replaced by —C(O)—R 5 , which is selected from the group consisting of the substituents according to Table 3 above.
a functionalized —NH 2 side chain group such as functionalized Lys, Orn, Dab or Dap
X14 represents an amino acid residue selected from Lys, Orn, Dab and Dap, wherein the —NH 2 side chain group is functionalized by —C(O)—R 5
X40 represents an amino acid residue selected from Lys, Orn, Dab and Dap, wherein the —NH 2 side chain group can be functionalized by —C(O)—R 5
—C(O)—R 5 is selected from the group consisting of the substituents according to Table 3 above.
position X14 and/or X40 in formula (II) represents Lysine (Lys).
Lys at position 14 and optionally at position 40 is functionalized, e.g. with a group —C(O)R 5 as described above.
X40 is absent and X14 is Lys functionalized with —C(O)—R 5 , —C(O)O—R 5 , —C(O)NH—R 5 , —S(O) 2 —R 5 or R 5 , preferably by —C(O)—R 5 , wherein R 5 is as defined above.
X14 is Lys functionalized with C(O)—R 5 , wherein R 5 is selected from the group consisting of (S)-4-carboxy-4-hexadecanoylamino-butyryl ( ⁇ E-x53), (S)-4-carboxy-4-octadecanoylamino-butyryl ( ⁇ E-x70), 4-hexadecanoylamino-butyryl (GABA-x53), 4- ⁇ 3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-tri methyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino ⁇ -butyryl-(GABA-x60), 4-octadecanoylamino-butyryl (GABA-x70), 4-((Z)-octadec-9-enoylamino)-butyryl (GABA-x74), 6-[(4,4--
X14 is Lys functionalized with C(O)—R 5 , wherein R 5 is selected from the group consisting of (S)-4-carboxy-4-hexadecanoylamino-butyryl ( ⁇ E-x53) and (S)-4-carboxy-4-octadecanoylamino-butyryl ( ⁇ E-x70).
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
a further embodiment relates to a group of compounds, wherein
peptidic compounds of formula (I) are the compounds of SEQ ID NO: 8-13 as well as salts and solvates thereof.
peptidic compounds of formula (I) are the compounds of SEQ ID NO: 8-10 and 13 as well as salts and solvates thereof.
the invention further provides a nucleic acid (which may be DNA or RNA) encoding said compound, an expression vector comprising such a nucleic acid, and a host cell containing such a nucleic acid or expression vector.
a nucleic acid which may be DNA or RNA
the present invention provides a composition comprising a compound of the invention in admixture with a carrier.
the composition is a pharmaceutically acceptable composition and the carrier is a pharmaceutically acceptable carrier.
the compound of the invention may be in the form of a salt, e.g. a pharmaceutically acceptable salt or a solvate, e.g. a hydrate.
the present invention provides a composition for use in a method of medical treatment, particularly in human medicine.
the nucleic acid or the expression vector may be used as therapeutic aguponents, e.g. in gene therapy.
the compounds of formula (I) are suitable for therapeutic application without an additionally therapeutically effective agent. In other embodiments, however, the compounds are used together with at least one additional therapeutically active agent, as described in “combination therapy”.
the compounds of formula (I) are particularly suitable for the treatment or prevention of diseases or disorders caused by, associated with and/or accompanied by disturbances in carbohydrate and/or lipid metabolism, e.g. for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity and metabolic syndrome. Further, the compounds of the invention are particularly suitable for the treatment or prevention of degenerative diseases, particularly neurodegenerative diseases.
the compounds described find use, inter alia, in preventing weight gain or promoting weight loss.
preventing is meant inhibiting or reducing when compared to the absence of treatment, and is not necessarily meant to imply complete cessation of a disorder.
the compounds of the invention may cause a decrease in food intake and/or increase in energy expenditure, resulting in the observed effect on body weight.
the compounds of the invention may have a beneficial effect on circulating cholesterol levels, being capable of improving lipid levels, particularly LDL, as well as HDL levels (e.g. increasing HDL/LDL ratio).
the compounds of the invention can be used for direct or indirect therapy of any condition caused or characterised by excess body weight, such as the treatment and/or prevention of obesity, morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea. They may also be used for treatment and prevention of the metabolic syndrome, diabetes, hypertension, atherogenic dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease, or stroke. Their effects in these conditions may be as a result of or associated with their effect on body weight, or may be independent thereof.
Preferred medical uses include delaying or preventing disease progression in type 2 diabetes, treating metabolic syndrome, treating obesity or preventing overweight, for decreasing food intake, increase energy expenditure, reducing body weight, delaying the progression from impaired glucose tolerance (IGT) to type 2 diabetes; delaying the progression from type 2 diabetes to insulin-requiring diabetes; regulating appetite; inducing satiety; preventing weight regain after successful weight loss; treating a disease or state related to overweight or obesity; treating bulimia; treating binge eating; treating atherosclerosis, hypertension, type 2 diabetes, IGT, dyslipidemia, coronary heart disease, hepatic steatosis, treatment of beta-blocker poisoning, use for inhibition of the motility of the gastrointestinal tract, useful in connection with investigations of the gastrointestinal tract using techniques such as X-ray, CT- and NMR-scanning.
ITT impaired glucose tolerance
Further preferred medical uses include treatment or prevention of degenerative disorders, particularly neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ataxia, e.g spinocerebellar ataxia, Kennedy disease, myotonic dystrophy, Lewy body dementia, multi-systemic atrophy, amyotrophic lateral sclerosis, primary lateral sclerosis, spinal muscular atrophy, prion-associated diseases, e.g.
neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ataxia, e.g spinocerebellar ataxia, Kennedy disease, myotonic dystrophy, Lewy body dementia, multi-systemic atrophy, amyotrophic lateral sclerosis, primary lateral sclerosis, spinal muscular atrophy, prion-associated diseases, e.g.
Creutzfeldt-Jacob disease multiple sclerosis, telangiectasia, Batten disease, corticobasal degeneration, subacute combined degeneration of spinal cord, Tabes dorsalis, Tay-Sachs disease, toxic encephalopathy, infantile Refsum disease, Refsum disease, neuroacanthocytosis, Niemann-Pick disease, Lyme disease, Machado-Joseph disease, Sandhoff disease, Shy-Drager syndrome, wobbly hedgehog syndrome, proteopathy, cerebral ⁇ -amyloid angiopathy, retinal ganglion cell degeneration in glaucoma, synucleinopathies, tauopathies, frontotemporal lobar degeneration (FTLD), dementia, cadasil syndrome, hereditary cerebral hemorrhage with amyloidosis, Alexander disease, seipinopathies, familial amyloidotic neuropathy, senile systemic amyloidosis, serpinopathies, AL (light chain) amyloido
Further medical uses include treatment of bone related disorders, such as osteoporosis or osteoarthritis, etc., where increased bone formation and decreased bone resorption might be beneficial.
amino acid sequences of the present invention contain the conventional one letter and three letter codes for naturally occuring amino acids, as well as generally accepted three letter codes for other amino acids, such as Aib ( ⁇ -aminoisobutyric acid), Orn (ornithin), Dab (2,4-diamino butyric acid), Dap (2,3-diamino propionic acid), Nle (norleucine), GABA ( ⁇ -aminobutyric acid) or Ahx ( ⁇ -aminohexanoic acid).
Aib ⁇ -aminoisobutyric acid
Orn ornithin
Dab 2,4-diamino butyric acid
Dap 2,3-diamino propionic acid
Nle nodeucine
GABA ⁇ -aminobutyric acid
Ahx ⁇ -aminohexanoic acid
native exendin-4 refers to native exendin-4 having the sequence HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 (SEQ ID NO: 1).
the invention provides peptidic compounds as defined above.
the peptidic compounds of the present invention comprise a linear backbone of amino carboxylic acids linked by peptide, i.e. carboxamide bonds.
the amino carboxylic acids are ⁇ -amino carboxylic acids and more preferably L- ⁇ -amino carboxylic acids, unless indicated otherwise.
the peptidic compounds preferably comprise a backbone sequence of 39-40 amino carboxylic acids.
the peptidic compounds of the present invention may have unmodified side-chains, but carry at least one modification at one of the side chains.
sequence of the peptidic moiety (II) differs from native exendin-4 at least at one of those positions which are stated to allow variation.
Amino acids within the peptide moiety (II) can be considered to be numbered consecutively from 0 to 40 in the conventional N-terminal to C-terminal direction.
Reference to a “position” within peptidic moiety (II) should be constructed accordingly, as should reference to positions within native exendin-4 and other molecules, e.g., in exendin-4, His is at position 1, Gly at position 2, . . . , Met at position 14, . . . and Ser at position 39.
amino acid residues at position 14 and optionally at position 40, having a side chain with an —NH 2 group, e.g. Lys, Orn, Dab or Dap are conjugated to a functional group, e.g. acyl groups.
a functional group e.g. acyl groups.
one or more selected amino acids of the peptides in the present invention may carry a covalent attachment at their side chains. In some cases those attachments may be lipophilic. These lipophilic side chain attachments have the potential to reduce in vivo clearance of the peptides thus increasing their in vivo half-lives.
the lipophilic attachment may consist of a lipophilic moiety which can be a branched or unbranched, aliphatic or unsaturated acyclic moiety and/or a cyclic moiety selected from one or several aliphatic or unsaturated homocycles or heterocycles, aromatic condensed or non-condensed homocycles or heterocycles, ether linkages, unsaturated bonds and substituents, e.g. hydroxy and/or carboxy groups.
the lipophilic moiety may be attached to the peptide either by alkylation, reductive amination or by an amide bond, a carbamate or a sulfonamide bond in case of amino acids carrying an amino group at their side chain.
Nonlimiting examples of lipophilic moieties that can be attached to amino acid side chains include fatty acids, e.g. C 8-30 fatty acids such as palmitic acid, myristic acid, stearic acid and oleic acid, and/or cyclic groups as described above or derivatives thereof.
linkers between the amino acid of the peptide and the lipophilic attachment.
linkers are ⁇ -alanine, ⁇ -glutamic acid, ⁇ -glutamic acid, ⁇ -aminobutyric acid and/or ⁇ -aminohexanoic acid or dipeptides, such as ⁇ -Ala- ⁇ -Ala (also abbreviated ⁇ A- ⁇ A herein) and/or ⁇ -Glu- ⁇ -Glu (also abbreviated ⁇ E- ⁇ E herein) in all their stereo-isomer forms (S and R enantiomers).
a side chain attachment is palmitic acid which is covalently linked to the ⁇ -amino group of glutamic acid forming an amide bond.
the ⁇ -carboxy group of this substituted glutamic acid can form an amide bond with the side chain amino group of a lysine within the peptide.
the present invention provides a composition
a composition comprising a compound of the invention as described herein, or a salt or solvate thereof, in admixture with a carrier.
the invention also provides the use of a compound of the present invention for use as a medicament, particularly for the treatment of a condition as described below.
the invention also provides a composition wherein the composition is a pharmaceutically acceptable composition, and the carrier is a pharmaceutically acceptable carrier.
peptides that are described in this invention. These methods include but are not limited to synthetic approaches and recombinant gene expression. Thus, one way of preparing these peptides is the synthesis in solution or on a solid support and subsequent isolation and purification. A different way of preparing the peptides is gene expression in a host cell in which a DNA sequence encoding the peptide has been introduced. Alternatively, the gene expression can be achieved without utilizing a cell system. The methods described above may also be combined in any way.
a preferred way to prepare the peptides of the present invention is solid phase synthesis on a suitable resin.
Solid phase peptide synthesis is a well established methodology (see for example: Stewart and Young, Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, III., 1984; E. Atherton and R. C. Sheppard, Solid Phase Peptide Synthesis. A Practical Approach, Oxford-IRL Press, New York, 1989).
Solid phase synthesis is initiated by attaching an N-terminally protected amino acid with its carboxy terminus to an inert solid support carrying a cleavable linker.
This solid support can be any polymer that allows coupling of the initial amino acid, e.g.
trityl resin a chlorotrityl resin, a Wang resin or a Rink resin in which the linkage of the carboxy group (or carboxamide for Rink resin) to the resin is sensitive to acid (when Fmoc strategy is used).
the polymer support must be stable under the conditions used to deprotect the ⁇ -amino group during the peptide synthesis.
the ⁇ -amino protecting group of this amino acid is removed.
the remaining protected amino acids are then coupled one after the other in the order represented by the peptide sequence using appropriate amide coupling reagents, for example BOP, HBTU, HATU or DIC (N,N′-diisopropylcarbodiimide)/HOBt (1-hydroxybenzotriazol), wherein BOP, HBTU and HATU are used with tertiary amine bases.
the liberated N-terminus can be functionalized with groups other than amino acids, for example carboxylic acids, etc.
a lysine may be protected with an ivDde ([1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl) protecting group (S. R. Chhabra et al., Tetrahedron Lett. 39, (1998), 1603) which is labile to a very nucleophilic base, for example 4% hydrazine in DMF (dimethyl formamide).
the ivDde group can be selectively removed using 4% hydrazine in DMF and the corresponding free amino group can then be further modified, e.g. by acylation.
the lysine can alternatively be coupled to a protected amino acid and the amino group of this amino acid can then be deprotected resulting in another free amino group which can be acylated or attached to further amino acids.
peptide is cleaved from the resin. This can be achieved by using King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 36, 1990, 255-266).
the raw material can then be purified by chromatography, e.g. preparative RP-HPLC, if necessary.
the term “potency” or “in vitro potency” is a measure for the ability of a compound to activate the receptors for GLP-1, GIP or glucagon in a cell-based assay. Numerically, it is expressed as the “EC50 value”, which is the effective concentration of a compound that induces a half maximal increase of response (e.g. formation of intracellular cAMP) in a dose-response experiment.
the compounds of the invention are agonists for the receptors for GLP-1 and for GIP as well as optionally the glucagon receptor (e.g. “dual or trigonal agonists”).
glucagon receptor e.g. “dual or trigonal agonists”.
Such peptides that are GIP/GLP-1 co-agonists, or GIP/GLP-1/glucagon tri-agonists may provide therapeutic benefit to address a clinical need for targeting the metabolic syndrome by allowing simultaneous treatment of diabetes and obesity.
Metabolic syndrome is a combination of medical disorders that, when occurring together, increase the risk of developing type 2 diabetes, as well as atherosclerotic vascular disease, e.g. heart disease and stroke.
Defining medical parameters for the metabolic syndrome include diabetes mellitus, impaired glucose tolerance, raised fasting glucose, insulin resistance, urinary albumin secretion, central obesity, hypertension, elevated triglycerides, elevated LDL cholesterol and reduced HDL cholesterol.
Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health and life expectancy and due to its increasing prevalence in adults and children it has become one of the leading preventable causes of death in modern world. It increases the likelihood of various other diseases, including heart disease, type 2 diabetes, obstructive sleep apnea, certain types of cancer, as well as osteoarthritis, and it is most commonly caused by a combination of excess food intake, reduced energy expenditure, as well as genetic susceptibility.
Diabetes mellitus often simply called diabetes, is a group of metabolic diseases in which a person has high blood sugar levels, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced.
the most common types of diabetes are: (1) type 1 diabetes, where the body fails to produce insulin; (2) type 2 diabetes, where the body fails to use insulin properly, combined with an increase in insulin deficiency over time, and (3) gestational diabetes, where women develop diabetes due to their pregnancy. All forms of diabetes increase the risk of long-term complications, which typically develop after many years.
macrovascular disease arising from atherosclerosis of larger blood vessels
microvascular disease arising from damage of small blood vessels.
macrovascular disease conditions are ischemic heart disease, myocardial infarction, stroke and peripheral vascular disease.
microvascular diseases are diabetic retinopathy, diabetic nephropathy, as well as diabetic neuropathy.
the receptors for GLP-1 and GIP as well as glucagon are members of the family of 7-transmembrane-spanning, heterotrimeric G-protein coupled receptors. They are structurally related to each other and share not only a significant level of sequence identity, but have also similar mechanisms of ligand recognition and intracellular signaling pathways.
GLP-1, GIP and glucagon share regions of high sequence identity/similarity.
GLP-1 and glucagon are produced from a common precursor, preproglucagon, which is differentially processed in a tissue-specific manner to yield e.g. GLP-1 in intestinal endocrine cells and glucagon in alpha cells of pancreatic islets.
GIP is derived from a larger proGIP prohormone precursor and is synthesized and released from K-cells located in the small intestine.
the peptidic incretin hormones GLP-1 and GIP are secreted by intestinal endocrine cells in response to food and account for up to 70% of meal-stimulated insulin secretion.
targeting of the GLP-1 receptor with suitable agonists offers an attractive approach for treatment of metabolic disorders, including diabetes.
the receptor for GLP-1 is distributed widely, being found mainly in pancreatic islets, brain, heart, kidney and the gastrointestinal tract. In the pancreas, GLP-1 acts in a strictly glucose-dependent manner by increasing secretion of insulin from beta cells.
GIP GLP-1 receptors
the receptor for GIP is broadly expressed in peripheral tissues including pancreatic islets, adipose tissue, stomach, small intestine, heart, bone, lung, kidney, testis, adrenal cortex, pituitary, endothelial cells, trachea, spleen, thymus, thyroid and brain.
pancreatic B-cell express the highest levels of the receptor for GIP in humans.
GIP-receptor mediated signaling could be impaired in patients with T2DM but GIP-action is shown to be reversible and could be restored with improvement of the diabetic status.
the stimulation of insulin secretion by both incretin hormones, GIP and GLP-1 is strictly glucosed-dependent ensuring a fail-safe mechanism associated with at low risk for hypoglycemia.
GLP-1 and GIP have been shown to promote glucose sensitivity, neogenesis, proliferation, transcription of proinsulin and hypertrophy, as well as antiapoptosis.
a peptide with dual agonistic activity for the GLP-1 and the GIP receptor could be anticipated to have additive or synergistic anti-diabetic benefit.
Other relevant effects of GLP-1 beyond the pancreas include delayed gastric emptying, increased satiety, decreased food intake, reduction of body weight, as well as neuroprotective and cardioprotective effects. In patients with type 2 diabetes, such extrapancreatic effects could be particularly important considering the high rates of comorbidities like obesity and cardiovascular disease.
Further GIP actions in peripheral tissues beyond the pancreas comprise increased bone formation and decreased bone resorption as well as neuroprotective effects which might be beneficial for the treatment of osteoporosis and cognitive defects like Alzheimer's disease.
Glucagon is a 29 amino acid peptide hormone that is produced by pancreatic alpha cells and released into the bloodstream when circulating glucose is low.
An important physiological role of glucagon is to stimulate glucose output in the liver, which is a process providing the major counterregulatory mechanism for insulin in maintaining glucose homeostasis in vivo.
Glucagon receptors are however also expressed in extrahepatic tissues such as kidney, heart, adipocytes, lymphoblasts, brain, retina, adrenal gland and gastrointestinal tract, suggesting a broader physiological role beyond glucose homeostasis. Accordingly, recent studies have reported that glucagon has therapeutically positive effects on energy management, including stimulation of energy expenditure and thermogenesis, accompanied by reduction of food intake and body weight loss. Altogether, stimulation of glucagon receptors might be useful in the treatment of obesity and the metabolic syndrome.
Oxyntomodulin is a peptide hormone consisting of glucagon with an eight amino acids encompassing C-terminal extension. Like GLP-1 and glucagon, it is preformed in preproglucagon and cleaved and secreted in a tissue-specific manner by endocrinal cells of the small bowel. Oxyntomodulin is known to stimulate both, the receptors for GLP-1 and glucagon and is therefore the prototype of a dual agonist.
GLP-1 and GIP are known for their anti-diabetic effects
GLP-1 and glucagon are both known for their food intake-suppressing effects
glucagon is also a mediator of additional energy expenditure, it is conceivable that a combination of the activities of the two or three hormones in one molecule can yield a powerful medication for treatment of the metabolic syndrome and in particular its components diabetes and obesity.
the compounds of the invention may be used for treatment of glucose intolerance, insulin resistance, pre-diabetes, increased fasting glucose, type 2 diabetes, hypertension, dyslipidemia, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or any combination of these individual disease components.
they may be used for control of appetite, feeding and calory intake, increase of energy expenditure, prevention of weight gain, promotion of weight loss, reduction of excess body weight and altogether treatment of obesity, including morbid obesity.
the effects of the compounds of the invention may be mediated in whole or in part via an effect on body weight, or independent thereof.
diseases to be treated are neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, or other degenerative diseases as described above.
exendin-4 Compared to GLP-1, glucagon and oxyntomodulin, exendin-4 has beneficial physicochemical properties, such as solubility and stability in solution and under physiological conditions (including enzymatic stability towards degradation by enzymes, such as DPP-4 or NEP), which results in a longer duration of action in vivo. Therefore, exendin-4 might serve as good starting scaffold to obtain exendin-4 analogs with dual or even triple pharmacologies, e.g., GLP-1/GIP and optionally in addition glucagon agonism.
exendin-4 has been shown to be chemically labile due to methionine oxdiation in position 14 as well as deamidation and isomerization of asparagine in position 28. Therefore, stability might be further improved by substitution of methionine at position 14 and the avoidance of sequences that are known to be prone to degradation via aspartimide formation, especially Asp-Gly or Asn-Gly at positions 28 and 29.
composition indicates a mixture containing ingredients that are compatible when mixed and which may be administered.
a pharmaceutical composition may include one or more medicinal drugs. Additionally, the pharmaceutical composition may include carriers, buffers, acidifying agents, alkalizing agents, solvents, adjuvants, tonicity adjusters, emollients, expanders, preservatives, physical and chemical stabilizers e.g. surfactants, antioxidants and other components, whether these are considered active or inactive ingredients.
Guidance for the skilled in preparing pharmaceutical compositions may be found, for example, in Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro A. R., 2000, Lippencott Williams & Wilkins and in R. C. Rowe et al (Ed), Handbook of Pharmaceutical Excipients, PhP, May 2013 update.
exendin-4 peptide derivatives of the present invention, or salts thereof, are administered in conjunction with an acceptable pharmaceutical carrier, diluent, or excipient as part of a pharmaceutical composition.
a “pharmaceutically acceptable carrier” is a carrier which is physiologically acceptable (e.g. physiologically acceptable pH) while retaining the therapeutic properties of the substance with which it is administered.
Standard acceptable pharmaceutical carriers and their formulations are known to one skilled in the art and described, for example, in Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro A. R., 2000, Lippencott Williams & Wilkins and in R. C. Rowe et al (Ed), Handbook of Pharmaceutical excipients, PhP, May 2013 update.
One exemplary pharmaceutically acceptable carrier is physiological saline solution.
carriers are selected from the group of buffers (e.g. citrate/citric acid), acidifying agents (e.g. hydrochloric acid), alkalizing agents (e.g. sodium hydroxide), preservatives (e.g. phenol), co-solvents (e.g. polyethylene glycol 400), tonicity adjusters (e.g. mannitol), stabilizers (e.g. surfactant, antioxidants, amino acids).
buffers e.g. citrate/citric acid
acidifying agents e.g. hydrochloric acid
alkalizing agents e.g. sodium hydroxide
preservatives e.g. phenol
co-solvents e.g. polyethylene glycol 400
tonicity adjusters e.g. mannitol
stabilizers e.g. surfactant, antioxidants, amino acids
Concentrations used are in a range that is physiologically acceptable.
Acceptable pharmaceutical carriers or diluents include those used in formulations suitable for oral, rectal, nasal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and transdermal) administration.
the compounds of the present invention will typically be administered parenterally.
pharmaceutically acceptable salt means salts of the compounds of the invention which are safe and effective for use in mammals.
Pharmaceutically acceptable salts may include, but are not limited to, acid addition salts and basic salts.
acid addition salts include chloride, sulfate, hydrogen sulfate, (hydrogen) phosphate, acetate, citrate, tosylate or mesylate salts.
basic salts include salts with inorganic cations, e.g. alkaline or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts and salts with organic cations such as amine salts. Further examples of pharmaceutically acceptable salts are described in Remington: The Science and Practice of Pharmacy, (20th ed.) ed.
solvate means complexes of the compounds of the invention or salts thereof with solvent molecules, e.g. organic solvent molecules and/or water.
the exendin-4 derivative in monomeric or oligomeric form.
terapéuticaally effective amount of a compound refers to a nontoxic but sufficient amount of the compound to provide the desired effect.
the amount of a compound of the formula I necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient.
An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation
the “therapeutically effective amount” of a compound of the formula (I) is about 0.01 to 50 mg/dose, preferably 0.1 to 10 mg/dose.
compositions of the invention are those suitable for parenteral (for example subcutaneous, intramuscular, intradermal or intravenous), oral, rectal, topical and peroral (for example sublingual) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula I used in each case.
Suitable pharmaceutical compositions may be in the form of separate units, for example capsules, tablets and powders in vials or ampoules, each of which contains a defined amount of the compound; as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. It may be provided in single or multiple dose injectable form, for example in the form of a pen.
the compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact.
the pharmaceutical composition may be provided together with a device for application, for example together with a syringe, an injection pen or an autoinjector.
a device for application for example together with a syringe, an injection pen or an autoinjector.
Such devices may be provided separate from a pharmaceutical composition or prefilled with the pharmaceutical composition.
the compounds of the present invention can be widely combined with other pharmacologically active compounds, such as all drugs mentioned in the Rote Liste 2012 and/or the Rote Liste 2013, e.g. with all antidiabetics mentioned in the Rote Liste 2012, chapter 12, and/or the Rote Liste 2013, chapter 12, all weight-reducing agents or appetite suppressants mentioned in the Rote Liste 2012, chapter 1, and/or the Rote Liste 2013, chapter 1, all lipid-lowering agents mentioned in the Rote Liste 2012, chapter 58, and/or the Rote Liste 2013, chapter 58, all antihypertensives and nephroprotectives, mentioned in the Rote Liste 2012 and/or the Rote Liste 2013, or all diuretics mentioned in the Rote Liste 2012, chapter 36, and/or the Rote Liste 2013, chapter 36.
the active ingredient combinations can be used especially for a synergistic improvement in action. They can be applied either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. When the active ingredients are administered by separate administration of the active ingredients, this can be done simultaneously or successively.
active substances which are suitable for such combinations include in particular those which for example potentiate the therapeutic effect of one or more active substances with respect to one of the indications mentioned and/or which allow the dosage of one or more active substances to be reduced.
Therapeutic agents which are suitable for combinations include, for example, antidiabetic agents such as:
Insulin and Insulin derivatives for example: Glargine/Lantus®, 270-330U/mL of insulin glargine (EP 2387989 A), 300U/mL of insulin glargine (EP 2387989 A), Glulisin/Apidra®, Detemir/Levemir®, Lispro/Humalog®/Liprolog®, Degludec/DegludecPlus, Aspart, basal insulin and analogues (e.g.
Exubera® Nasulin®, Afrezza, Tregopil, TPM 02, Capsulin, Oral-lyn®, Cobalamin® oral insulin, ORMD-0801, NN1953, NN1954, NN1956, VIAtab, Oshadi oral insulin). Additionally included are also those insulin derivatives which are bonded to albumin or another protein by a bifunctional linker.
GLP-1, GLP-1 analogues and GLP-1 receptor agonists for example: Lixisenatide/AVE0010/ZP10/Lyxumia, Exenatide/Exendin-4/Byetta/Bydureon/ITCA 650/AC-2993, Liraglutide/Victoza, Semaglutide, Taspoglutide, Syncria/Albiglutide, Dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-112600, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM
DPP-4 inhibitors for example: Alogliptin/Nesina, Trajenta/Linagliptin/BI-1356/Ondero/Trajenta/Tradjenta/Trayenta/Tradzenta, Saxagliptin/Onglyza, Sitagliptin/Januvia/Xelevia/Tesave/Janumet/Velmetia, Galvus/Vildagliptin, Anagliptin, Gemigliptin, Teneligliptin, Melogliptin, Trelagliptin, DA-1229, Omarigliptin/MK-3102, KM-223, Evogliptin, ARI-2243, PBL-1427, Pinoxacin.
Alogliptin/Nesina Trajenta/Linagliptin/BI-1356/Ondero/Trajenta/Tradjenta/Trayenta/Tradzenta
SGLT2 inhibitors for example: Invokana/Canaglifozin, Forxiga/Dapagliflozin, Remoglifozin, Sergliflozin, Empagliflozin, Ipragliflozin, Tofogliflozin, Luseogliflozin, LX-4211, Ertuglifozin/PF-04971729, RO-4998452, EGT-0001442, KGA-3235/DSP-3235, LIK066, SBM-TFC-039,
Biguanides e.g. Metformin, Buformin, Phenformin
Thiazolidinediones e.g. Pioglitazone, Rivoglitazone, Rosiglitazone, Troglitazone
dual PPAR agonists e.g. Aleglitazar, Muraglitazar, Tesaglitazar
Sulfonylureas e.g. Tolbutamide, Glibenclamide, Glimepiride/Amaryl, Glipizide
Meglitinides e.g. Nateglinide, Repaglinide, Mitiglinide
Alpha-glucosidase inhibitors e.g. Acarbose, Miglitol, Voglibose
Amylin and Amylin analogues e.g. Pramlintide, Symlin.
GPR119 agonists e.g. GSK-263A, PSN-821, MBX-2982, APD-597, ZYG-19, DS-8500
GPR40 agonists e.g. Fasiglifam/TAK-875, TUG-424, P-1736, JTT-851, GW9508.
Suitable combination partners are: Cycloset, inhibitors of 11-beta-HSD (e.g. LY2523199, BMS770767, RG-4929, BMS816336, AZD-8329, HSD-016, BI-135585), activators of glucokinase (e.g. TTP-399, AMG-151, TAK-329, GKM-001), inhibitors of DGAT (e.g. LCQ-908), inhibitors of protein tyrosinephosphatase 1 (e.g.
Trodusquemine inhibitors of glucose-6-phosphatase, inhibitors of fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, inhibitors of phosphoenol pyruvate carboxykinase, inhibitors of glycogen synthase kinase, inhibitors of pyruvate dehydrokinase, alpha2-antagonists, CCR-2 antagonists, SGLT-1 inhibitors (e.g. LX-2761).
One or more lipid lowering agents are also suitable as combination partners, such as for example: HMG-CoA-reductase inhibitors (e.g. Simvastatin, Atorvastatin), fibrates (e.g. Bezafibrate, Fenofibrate), nicotinic acid and the derivatives thereof (e.g. Niacin), PPAR-(alpha, gamma or alpha/gamma) agonists or modulators (e.g. Aleglitazar), PPAR-delta agonists, ACAT inhibitors (e.g. Avasimibe), cholesterol absorption inhibitors (e.g. Ezetimibe), Bile acid-binding substances (e.g. Cholestyramine), ileal bile acid transport inhibitors, MTP inhibitors, or modulators of PCSK9.
HMG-CoA-reductase inhibitors e.g. Simvastatin, Atorvastatin
fibrates e.g. Bezafib
HDL-raising compounds such as: CETP inhibitors (e.g. Torcetrapib, Anacetrapid, Dalcetrapid, Evacetrapid, JTT-302, DRL-17822, TA-8995) or ABC1 regulators.
CETP inhibitors e.g. Torcetrapib, Anacetrapid, Dalcetrapid, Evacetrapid, JTT-302, DRL-17822, TA-8995
ABC1 regulators e.g., ABC1 regulators.
Suitable combination partners are one or more active substances for the treatment of obesity, such as for example: Sibutramine, Tesofensine, Orlistat, antagonists of the cannabinoid-1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists (e.g. Velneperit), beta-3-agonists, leptin or leptin mimetics, agonists of the 5HT2c receptor (e.g. Lorcaserin), or the combinations of bupropione/naltrexone, bupropione/zonisamide, bupropione/phentermine or pramlintide/metreleptin.
active substances for the treatment of obesity such as for example: Sibutramine, Tesofensine, Orlistat, antagonists of the cannabinoid-1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists (e.g. Velneperit), beta-3-agonists,
gastrointestinal peptides such as Peptide YY 3-36 (PYY3-36) or analogues thereof, pancreatic polypeptide (PP) or analogues thereof.
Glucagon receptor agonists or antagonists GIP receptor agonists or antagonists, ghrelin antagonists or inverse agonists, Xenin and analogues thereof.
angiotensin II receptor antagonists e.g. telmisartan, candesartan, valsartan, losartan, eprosartan, irbesartan, olmesartan, tasosartan, azilsartan
ACE inhibitors e.g. telmisartan, candesartan, valsartan, losartan, eprosartan, irbesartan, olmesartan, tasosartan, azilsartan
ACE inhibitors e.g. telmisartan, candesartan, valsartan, losartan, eprosartan, irbesartan, olmesartan, tasosartan, azilsartan
ACE inhibitors e.g. telmisartan, candesartan, valsartan, losartan, eprosartan, irbe
this invention relates to the use of a compound according to the invention or a physiologically acceptable salt thereof combined with at least one of the active substances described above as a combination partner, for preparing a medicament which is suitable for the treatment or prevention of diseases or conditions which can be affected by binding to the receptors for GLP-1 and glucagon and by modulating their activity.
This is preferably a disease in the context of the metabolic syndrome, particularly one of the diseases or conditions listed above, most particularly diabetes or obesity or complications thereof.
the use of the compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may take place simultaneously or at staggered times, but particularly within a short space of time. If they are administered simultaneously, the two active substances are given to the patient together; if they are used at staggered times, the two active substances are given to the patient within a period of less than or equal to 12 hours, but particularly less than or equal to 6 hours.
this invention relates to a medicament which comprises a compound according to the invention or a physiologically acceptable salt of such a compound and at least one of the active substances described above as combination partners, optionally together with one or more inert carriers and/or diluents.
the compound according to the invention, or physiologically acceptable salt or solvate thereof, and the additional active substance to be combined therewith may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as so-called kit-of-parts.
FIG. 1 Effect of s.c. administration of compound SEQ ID NO: 10 at 3 ⁇ g/kg and 10 ⁇ g/kg on body weight in female diet-induced obese (DIO) C57BL/6NCrl mice following 3-weeks chronic treatment once daily. Data are mean ⁇ SEM.
FIG. 2 Effect of s.c. administration of compound SEQ ID NO: 10 at 3 ⁇ g/kg and 10 ⁇ g/kg on body weight in female diet-induced obese (DIO) C57BL/6NCrl mice following 3-weeks chronic treatment once daily. Changes in body weight were calculated as relative change from baseline. Data are mean ⁇ SEM.
FIG. 3 Effect of 4 weeks of treatment with SEQ ID NO: 10 at 3 and 10 ⁇ g/kg, s.c. on non-fasted glucose in diabetic dbdb-mice, represented as change from baseline (0 mmol/l, day ⁇ 7). Data are mean ⁇ SEM.
FIG. 4 Effect of 4 weeks of treatment with SEQ ID NO: 10 at 3 and 10 ⁇ g/kg, s.c. on HbA1c in diabetic dbdb-mice, represented as change from baseline (0%, day ⁇ 7). Data are mean ⁇ SEM.
FIG. 6 Effect of 4 weeks of treatment with SEQ ID NO: 10 at 3 and 10 ⁇ g/kg, s.c. on oral glucose tolerance in diabetic dbdb-mice, represented as area under the glucose curve (Glucose-AUC). Data are mean ⁇ SEM.
FIG. 7 Effect of treatment with SEQ ID NO: 13 at 3 ⁇ g/kg, s.c. on glucose lowering in non-fasted female diabetic dbdb-mice, represented as change from baseline. Data are mean ⁇ SEM.
FIG. 8 Effect of s.c. administration of compound SEQ ID NO: 10, 1, 10 and 100 ⁇ g/kg on gastric emptying and intestinal passage in female NMRI-mice. Data are mean ⁇ SEM.
FIG. 9 Effect of s.c. administration of compound SEQ ID NO: 10 at 3 and 10 ⁇ g/kg on 22-hours feed intake in female NMRI-mice. Data are mean ⁇ SEM. *p ⁇ 0.05.
Rink-Amide resins (4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin, Merck Biosciences; 4-[(2,4-Dimethoxyphenyl)(Fmoc-amino)methyl]phenoxy acetamido methyl resin, Agilent Technologies) were used for the synthesis of peptide amides with loadings in the range of 0.3-0.4 mmol/g.
Fmoc protected natural amino acids were purchased from Protein Technologies Inc., Senn Chemicals, Merck Biosciences, Novabiochem, Iris Biotech or Bachem. The following standard amino acids were used throughout the syntheses: Fmoc-L-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Asp(OtBu)-OH, Fmoc-L-Cys(Trt)-OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-L-His(Trt)-OH, Fmoc-L-Ile-OH, Fmoc-L-Leu-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Met-OH, Fmoc-L-
the solid phase peptide syntheses were performed for example on a Prelude Peptide Synthesizer (Protein Technologies Inc) or similar automated synthesizer using standard Fmoc chemistry and HBTU/DIPEA activation. DMF was used as the solvent. Deprotection: 20% piperidine/DMF for 2 ⁇ 2.5 min. Washes: 7 ⁇ DMF. Coupling 2:5:10 200 mM AA/500 mM HBTU/2M DIPEA in DMF 2 ⁇ for 20 min. Washes: 5 ⁇ DMF.
Fmoc-L-Lys(ivDde)-OH or Fmoc-L-Lys(Mmt)-OH was used in the corresponding position.
the ivDde group was removed according to a modified literature procedure (S. R. Chhabra et al., Tetrahedron Lett. 39, (1998), 1603), using 4% hydrazine hydrate in DMF.
the Mmt group was removed by repeated treatment with 1% TFA in dichloromethane.
the following acylations were carried out by treating the resin with the N-hydroxy succinimide esters of the desired acid or using coupling reagents like HBTU/DIPEA or HOBt/DIC.
a Waters LCT Premier Time-of-Flight instrument was used as mass analyser equipped with an electrospray in the positive ion mode.
the crude peptides were purified either on an Akta Purifier System or on a Jasco semiprep HPLC System. Preparative RP-C18-HPLC columns of different sizes and with different flow rates were used depending on the amount of crude peptide to be purified. Acetonitrile+0.05 to 0.1% TFA (B) and water+0.05 to 0.1% TFA (A) were employed as eluents. Alternatively, a buffer system consisting of acetonitrile and water with minor amounts of acetic acid was used. Product-containing fractions were collected and lyophilized to obtain the purified product, typically as TFA or acetate salt.
the target concentration was 1.0 mg/mL pure compound. Therefore, solutions from solid samples were prepared in different buffer systems with a concentration of 1.0 mg/mL compound based on the previously determined content. HPLC-UV was performed after 2 h of gentle agitation from the supernatant, which was obtained by 20 min of centrifugation at 4000 rpm.
solubility was then determined by comparison with the UV peak areas obtained with a stock solution of the peptide at a concentration of 2 mg/mL in pure water or a variable amount of acetonitrile (optical control that all of the compound was dissolved). This analysis also served as starting point (t0) for the stability testing.
the amount of soluble degradation products was calculated from the comparison of the sum of the peak areas from all observed impurities reduced by the sum of peak areas observed at t0 (i.e. to determine the amount of newly formed peptide-related species). This value was given in percentual relation to the initial amount of peptide at t0, following the equation:
% soluble degradation products ⁇ [(peak area sum of impurities t 7) ⁇ (peak area sum of impurities t 0)] ⁇ 100 ⁇ /peak area peptide t 0
This precipitate includes non-soluble degradation products, polymers and/or fibrils, which have been removed from analysis by centrifugation.
the chemical stability is expressed as “% remaining peptide”.
Agonism of compounds for the receptors was determined by functional assays measuring cAMP response of HEK-293 cell lines stably expressing human GIP, GLP-1 or glucagon receptor.
cAMP content of cells was determined using a kit from Cisbio Corp. (cat. no. 62AM4PEC) based on HTRF (Homogenous Time Resolved Fluorescence).
HTRF Homogenous Time Resolved Fluorescence
cells were split into T175 culture flasks and grown overnight to near confluency in medium (DMEM/10% FBS). Medium was then removed and cells washed with PBS lacking calcium and magnesium, followed by proteinase treatment with accutase (Sigma-Aldrich cat. no. A6964). Detached cells were washed and resuspended in assay buffer (1 ⁇ HBSS; 20 mM HEPES, 0.1% BSA, 2 mM IBMX) and cellular density determined.
test compound in assay buffer was added to the wells, followed by incubation for 30 minutes at room temperature.
HTRF reagents diluted in lysis buffer (kit components)
the plates were incubated for 1 hr, followed by measurement of the fluorescence ratio at 665/620 nm.
In vitro potency of agonists was quantified by determining the concentrations that caused 50% activation of maximal response (EC50).
mice were dosed 1 mg/kg subcutaneously (s.c.). The mice were sacrificed and blood samples were collected after 0.25, 0.5, 1, 2, 4, 8, 16 and 24 hours post application. Plasma samples were analyzed after protein precipitation via liquid chromatography mass spectrometry (LC/MS). PK parameters and half-life were calculated using WinonLin Version 5.2.1 (non-compartment model).
mice Female Gottinger minipigs were dosed 0.1 mg/kg subcutaneously (s.c.). Blood samples were collected after 0.25, 0.5, 1, 2, 4, 8, 24, 32, 48, 56 and 72 hours post application. Plasma samples were analyzed after protein precipitation via liquid chromatography mass spectrometry (LC/MS). PK parameters and half-life were calculated using WinonLin Version 5.2.1 (non-compartment model).
Method F AB Sciex API 4000, mass analyser: electrospray positive ion mode
mice Female NMRI-mice of a body weight between 20 and 30 g were used. Mice were adapted to housing conditions for at least one week.
mice were overnight fasted, while water remained available all the time. On the study day, mice were weighed, single-caged and allowed access to 500 mg of feed for 30 min, while water was removed. At the end of the 30 min feeding period, remaining feed was removed and weighed. Then, the test compound/reference compound or its vehicle in the control group was administered subcutaneously. 60 min later, to allow the compound to reach relevant plasma exposure, a coloured, non-caloric bolus was instilled via gavage into the stomach. After another 30 min, the animals were sacrificed and the stomach and the small intestine prepared. The filled stomach was weighed, emptied, carefully cleaned and dried and reweighed.
the stomach content calculated as weight of filled subtracted by the weight of emptied stomach, indicated the degree of gastric emptying.
the small intestine was straightened without force and measured in length. Then the distance from the gastric beginning of the gut to the tip of the farthest travelled intestinal content bolus was measured. The intestinal passage was given as ratio in percent of the latter distance and the total length of the small intestine.
mice Female NMRI-mice of a body weight between 20 and 30 g were used. Mice were adapted to housing conditions for at least one week and for at least one day single-caged in the assessment equipment, when basal data were recorded simultaneously. On the study day, test product was administered subcutaneously close to the lights-off phase (12 h lights off) and assessment of feed consumption was directly started afterwards. Assessment included continued monitoring over 22 hours, while data are processed as mean over every 30 min. Repetition of this procedure over several days was possible. Restriction of assessment to 22 hours was for practical reasons to allow for reweighing of animals, refilling of feed and water and drug administration between procedures. Results could be assessed as cumulated data over 22 hours or differentiated to 30 min intervals. Comparable data can be obtained for both female and male mice.
mice were subcutaneously (s.c.) injected with vehicle solution and weighed for 3 days to acclimate them to the procedures.
Acute effect on blood glucose in fed DIO mice initial blood samples were taken just before first administration (s.c.) of vehicle (phosphate buffer solution) or the exendin-4 derivatives at doses of 10, 30 and 100 ⁇ g/kg (dissolved in phosphate puffer), respectively. The volume of administration was 5 mL/kg. The animals had access to water and their corresponding diet during the experiment, food consumption was determined at all time points of blood sampling.
vehicle phosphate buffer solution
exendin-4 derivatives dissolved in phosphate puffer
mice were subcutaneously (s.c.) injected with vehicle solution and weighed for 3 days to acclimate them to the procedures.
Subchronic effect on body weight all animals were treated once daily s.c. late afternoon, at the end of the light phase (LD 12:12) with either vehicle or exendin-4 derivatives at the above-mentioned doses for 3 weeks. Body weight was recorded daily.
mice Female BKS.Cg-m+/+Leprdb/J (db/db) and BKS.Cg-m+/+Leprdb/+(lean control) mice were obtained from Charles River Laboratories, Germany, at an age of 9-10 weeks. The animals were housed in groups in a specific pathogen-free barrier facility on a 12-h light/dark cycle with free access to water and rodent-standard chow.
blood samples were drawn from the tail without anaesthesia and blood glucose (method: d-glucose hexokinase, hemolysate, AU640 Beckman Coulter) and HbA1c level (method: hemolysate, Cobas6000 c501, Roche Diagnostics, Germany) were determined.
HbA1c is a glycosylated form of haemoglobin whose level reflects the average level of glucose to which the erythrocyte has been exposed during its lifetime. In mice, HbA1c is a relevant biomarker for the average blood glucose level during the preceding 4 weeks (erythrocyte life span in mouse 47 days).
mice 8 week old, female diabetic dbdb-mice of mean non-fasted glucose value of 14.5 mmol/l and a body weight of 37-40 g were used. Mice were individually marked and were adapted to housing conditions for at least one week.
mice Female diabetic dbdb-mice of mean non-fasted glucose value of 20-22 mmol/l and a body weight of 42 g+/ ⁇ 0.6 g (SEM) were used. Mice were individually marked and were adapted to housing conditions for at least one week.
mice were assigned to groups and cages (4 mice per cage, 8 per group) according to their non-fasted glucose values to ensure even distribution of lower and higher values between groups (stratification).
t 0
t 0
t 0
a first blood sample at a tail incision was drawn (baseline). Further blood samples were drawn at the tail incision at 30, 60, 90, 120, 240, 360, and 480 min.
the solid phase synthesis was carried out on Novabiochem Rink-Amide resin (4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin), 100-200 mesh, loading of 0.34 mmol/g.
the Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. In position 1 Boc-Tyr(tBu)-OH and in position 14 Fmoc-Lys(ivDde)-OH was used in the solid phase synthesis protocol.
the ivDde-group was cleaved from the peptide on resin according to a modified literature procedure (S. R.
the solid phase synthesis was carried out on Novabiochem Rink-Amide resin (4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin), 100-200 mesh, loading of 0.34 mmol/g.
the Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. In position 1 Boc-Tyr(tBu)-OH and in position 14 Fmoc-Lys(ivDde)-OH was used in the solid phase synthesis protocol.
the ivDde-group was cleaved from the peptide on resin according to a modified literature procedure (S. R.
the solid phase synthesis was carried out on Novabiochem Rink-Amide resin (4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin), 100-200 mesh, loading of 0.34 mmol/g.
the Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. In position 1 Boc-Tyr(tBu)-OH and in position 14 Fmoc-Lys(ivDde)-OH was used in the solid phase synthesis protocol.
the ivDde-group was cleaved from the peptide on resin according to a modified literature procedure (S. R.
Solubility Solubility (pH 4.5) (pH 7.4) (pH 4.5) (pH 7.4) SEQ ID NO: [%] [%] [ ⁇ g/ml] [ ⁇ g/ml] 1 (Exendin-4) 100.0 77.5 933.6 1000 10 99.0 97.0 120.3 >1000 13 Not determined 84.0 688.0 824.0
Potencies of peptidic compounds at the GLP-1, GIP and glucagon receptors were determined by exposing cells expressing human glucagon receptor (hGLUC R), human GIP (hGIP R) and human GLP-1 receptor (hGLP-1 R) to the listed compounds at increasing concentrations and measuring the formed cAMP as described in Methods.
mice Female obese C57BL/6NCrl mice were treated for 3 weeks once daily subcutaneously in the late afternoon, prior to the end of the light phase (12 h lights on) with 3 ⁇ g/kg and 10 ⁇ g/kg SEQ ID NO: 10 or vehicle. Body weight was recorded daily.
SEQ ID NO: 10 prevented an increase of HbA1c in a statistical significant manner compared to vehicle control at the 10 ⁇ g/kg dose ( FIG. 4 ; p ⁇ 0.05, 1-way-ANOVA, followed by Dunnett's post-hoc test).
FIG. 5 Treatment with SEQ ID NO: 10 lead to improved oral glucose tolerance ( FIG. 5 ; represented as normalized to 0 mmol/l at 0 min), and reduction of AUC under the glucose curve reached statistical significance at 10 ⁇ g/kg compared to vehicle control ( FIG. 6 ; p ⁇ 0.05, 1-way-ANOVA, followed by Dunnett's post-hoc test).
Female dbdb-mice received 3 ⁇ g/kg of SEQ ID NO: 13 or phosphate buffered saline (vehicle control) subcutaneously, at time 0 min.
the compound immediately lowered glucose values (baseline at 20-22 mmol/l), reaching the maximal effect of ⁇ 12 mmol/l glucose reduction, at 240 min and keeping it to the end of observation at 480 min ( FIG. 7 ).
Female NMRI-mice weighing on average 25-30 g, received 1, 10 and 100 ⁇ g/kg of SEQ ID NO: 10, or phosphate buffered saline (vehicle control) subcutaneously, 30 min prior to the administration of the coloured bolus. 30 min later, the assessment of stomach contents and intestinal passage was done ( FIG. 8 ).
SEQ ID NO: 10 reduced intestinal passage by 28, 58 and 64% (p ⁇ 0.0001) and increased remaining gastric contents by 1, 28 and 68% (p ⁇ 0.0001 versus vehicle control, 1-W-ANOVA, followed by Dunnett's post-hoc test) respectively.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Immunology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)

US14/135,756 2012-12-21 2013-12-20 Exendin-4 Derivatives Abandoned US20140206608A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12306647		2012-12-21
EP12306647.4		2012-12-21

Publications (1)

Publication Number	Publication Date
US20140206608A1 true US20140206608A1 (en)	2014-07-24

Family

ID=47559233

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
US14/136,061 Expired - Fee Related US9745360B2 (en)	2012-12-21	2013-12-20	Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US14/135,756 Abandoned US20140206608A1 (en)	2012-12-21	2013-12-20	Exendin-4 Derivatives
US14/135,801 Active US9670261B2 (en)	2012-12-21	2013-12-20	Functionalized exendin-4 derivatives
US14/135,772 Abandoned US20140213513A1 (en)	2012-12-21	2013-12-20	Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists
US15/486,054 Active US10253079B2 (en)	2012-12-21	2017-04-12	Functionalized Exendin-4 derivatives

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
US14/136,061 Expired - Fee Related US9745360B2 (en)	2012-12-21	2013-12-20	Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
US14/135,801 Active US9670261B2 (en)	2012-12-21	2013-12-20	Functionalized exendin-4 derivatives
US14/135,772 Abandoned US20140213513A1 (en)	2012-12-21	2013-12-20	Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists
US15/486,054 Active US10253079B2 (en)	2012-12-21	2017-04-12	Functionalized Exendin-4 derivatives

Country Status (38)

Country	Link
US (5)	US9745360B2 (es)
EP (5)	EP2934566B1 (es)
JP (4)	JP2016503771A (es)
KR (4)	KR20150096398A (es)
CN (4)	CN104870009B (es)
AR (5)	AR094181A1 (es)
AU (4)	AU2013366692B2 (es)
BR (3)	BR112015014510A2 (es)
CA (4)	CA2895156A1 (es)
CL (2)	CL2015001751A1 (es)
CR (1)	CR20150358A (es)
CY (2)	CY1120030T1 (es)
DK (2)	DK2934567T3 (es)
DO (1)	DOP2015000156A (es)
EA (1)	EA031428B1 (es)
EC (1)	ECSP15031141A (es)
ES (2)	ES2688367T3 (es)
HK (3)	HK1211232A1 (es)
HR (2)	HRP20180092T1 (es)
HU (2)	HUE035803T2 (es)
IL (4)	IL238623A0 (es)
LT (2)	LT2934568T (es)
MA (1)	MA38276B1 (es)
MX (4)	MX362190B (es)
PE (1)	PE20151239A1 (es)
PH (1)	PH12015501291B1 (es)
PL (2)	PL2934568T3 (es)
PT (2)	PT2934567T (es)
RS (1)	RS57531B1 (es)
RU (3)	RU2652783C2 (es)
SG (5)	SG11201503526UA (es)
SI (2)	SI2934567T1 (es)
TN (1)	TN2015000283A1 (es)
TW (4)	TWI602828B (es)
UA (1)	UA116553C2 (es)
UY (4)	UY35231A (es)
WO (4)	WO2014096145A1 (es)
ZA (1)	ZA201503914B (es)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
US9365632B2 (en)	2012-10-09	2016-06-14	Sanofi	Exendin-4 derivatives as dual GLP1/glucagon agonists
US9670261B2 (en)	2012-12-21	2017-06-06	Sanofi	Functionalized exendin-4 derivatives
US9694053B2 (en)	2013-12-13	2017-07-04	Sanofi	Dual GLP-1/glucagon receptor agonists
US9751926B2 (en)	2013-12-13	2017-09-05	Sanofi	Dual GLP-1/GIP receptor agonists
US9750788B2 (en)	2013-12-13	2017-09-05	Sanofi	Non-acylated exendin-4 peptide analogues
US9758561B2 (en)	2014-04-07	2017-09-12	Sanofi	Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9771406B2 (en)	2014-04-07	2017-09-26	Sanofi	Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en)	2014-04-07	2017-10-03	Sanofi	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9789165B2 (en)	2013-12-13	2017-10-17	Sanofi	Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
US9982029B2 (en)	2015-07-10	2018-05-29	Sanofi	Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10806797B2 (en)	2015-06-05	2020-10-20	Sanofi	Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
US10894076B2 (en)	2015-12-29	2021-01-19	Pegbio Co., Ltd.	Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof
US11160869B2 (en)	2019-08-16	2021-11-02	Applied Molecular Transport Inc.	Compositions, formulations and interleukin production and purification
CN114848799A (zh) *	2015-05-28	2022-08-05	免疫新炉有限公司	用于肌肉减少症治疗的包括胰高血糖素样肽-1受体激动剂的药物组合物
US11485753B2 (en)	2012-12-21	2022-11-01	Janssen Pharmaceutica Nv	Substituted nucleosides, nucleotides and analogs thereof
US12215133B2 (en)	2021-03-25	2025-02-04	Brightgene Bio-Medical Technology Co., Ltd.	GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA111305C2 (uk)	2012-12-21	2016-04-11	Пфайзер Інк.	Конденсовані лактами арилу та гетероарилу
PE20151770A1 (es)	2013-05-28	2015-12-11	Takeda Pharmaceutical	Compuesto peptidico
US10131702B2 (en) *	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
EP3065767B1 (en)	2013-11-06	2020-12-30	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
BR112016029612B1 (pt)	2014-06-17	2021-01-19	Pfizer Inc.	compostos de di-hidroisoquinolinona substituídos
US10253078B2 (en)	2014-10-29	2019-04-09	Zealand Pharma A/S	GIP agonist compounds and methods
AR103322A1 (es)	2014-12-30	2017-05-03	Hanmi Pharm Ind Co Ltd	Derivados de glucagón con estabilidad mejorada
JOP20200119A1 (ar)	2015-01-09	2017-06-16	Lilly Co Eli	مركبات مساعد مشترك من gip وglp-1
US10993993B2 (en)	2015-05-28	2021-05-04	Immunoforge Co., Ltd.	Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
WO2016198624A1 (en) *	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
PT3322437T (pt)	2015-06-30	2024-03-20	Hanmi Pharmaceutical Co Ltd	Derivado de glucagon e composição que compreende um conjugado de ação prolongada do mesmo
TWI622596B (zh)	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
HUE053079T2 (hu) *	2015-12-14	2021-06-28	Antaros Medical Ab	Képalkotási célokból kelátképzõ részt tartalmazó szelektív glükagonreceptor-agonisták
ES2968038T3 (es)	2015-12-23	2024-05-06	Univ Johns Hopkins	Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas
EA038544B1 (ru) *	2015-12-31	2021-09-13	Ханми Фарм. Ко., Лтд.	Тройной агонист рецепторов глюкагона/glp-1/gip
SG10202109721PA (en) *	2016-03-10	2021-10-28	Medimmune Ltd	Glucagon and glp-1 co-agonists for the treatment of obesity
US10501516B2 (en)	2016-05-24	2019-12-10	Takeda Pharmaceutical Company Limited	Peptide compound
UA126662C2 (uk)	2016-06-29	2023-01-11	Ханмі Фарм. Ко., Лтд.	Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
TW201821434A (zh)	2016-10-10	2018-06-16	法商賽諾菲公司	製備包含親脂性修飾的離胺酸側鏈的肽的方法
EP3526242A1 (en) *	2016-10-12	2019-08-21	University of Copenhagen	Peptide dual agonists of gipr and glp2r
TW201833132A (zh) *	2016-12-02	2018-09-16	法商賽諾菲公司	作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
EP3585775B1 (en)	2017-02-21	2022-04-06	Sanofi	Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
JOP20180028A1 (ar)	2017-03-31	2019-01-30	Takeda Pharmaceuticals Co	مركب ببتيد
AU2018303625A1 (en) *	2017-07-19	2020-02-06	Novo Nordisk A/S	Bifunctional compounds
JP7230002B2 (ja)	2017-08-09	2023-02-28	サノフイ	脂肪性肝疾患および脂肪性肝炎の治療におけるｇｌｐ－１／グルカゴン受容体アゴニスト
CN120887972A (zh) *	2017-11-24	2025-11-04	浙江道尔生物科技有限公司	一种治疗代谢疾病的胰高血糖素类似物
GB201720187D0 (en)	2017-12-04	2018-01-17	Imperial Innovations Ltd	Novel Compounds
ES2925678T3 (es)	2018-04-05	2022-10-19	Sun Pharmaceutical Ind Ltd	Nuevos análogos de GLP-1
JP7434169B2 (ja)	2018-04-10	2024-02-20	サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	固相からの固相結合ペプチドの切断方法
AU2019250362B2 (en)	2018-04-10	2025-11-06	Sanofi-Aventis Deutschland Gmbh	Lixisenatide synthesis with capping
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202015735A (zh)	2018-05-30	2020-05-01	法商賽諾菲公司	包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
TW202535916A (zh) *	2018-11-01	2025-09-16	美商美國禮來大藥廠	蛋白質酪胺酸-酪胺酸類似物及其使用方法
KR102119188B1 (ko) *	2018-11-13	2020-06-08	이뮤노포지 주식회사	글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
BR112021011595A2 (pt)	2018-12-21	2021-11-30	Jiangsu Hengrui Medicine Co	Proteína biespecífica
EP3900735A4 (en) *	2018-12-21	2022-09-07	Hanmi Pharm. Co., Ltd.	PHARMACEUTICAL COMPOSITION WITH INSULIN AND TRIPLE AGONOISTS WITH ACTIVITY AGAINST ALL GLUCAGON AND GLP-1 AND GIP RECEPTORS
JP7324530B2 (ja) *	2019-01-07	2023-08-10	鴻緒生物医葯科技（北京）有限公司	新型ポリペプチド及びその治療用途
CA3136163A1 (en) *	2019-04-11	2020-10-15	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Multi-receptor agonist and medical use thereof
WO2020214012A1 (ko) *	2019-04-19	2020-10-22	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) *	2019-04-19	2020-10-22	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
GB201908424D0 (en)	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
CN111040022B (zh) *	2019-12-23	2021-12-14	万新医药科技(苏州)有限公司	针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
WO2021150673A1 (en) *	2020-01-23	2021-07-29	Eli Lilly And Company	Gip/glp1 co-agonist compounds
EP4110800A1 (en)	2020-03-06	2023-01-04	Sanofi	Peptides as selective gip receptor agonists
EP4171662A1 (en)	2020-03-31	2023-05-03	Antaros Medical AB	Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
WO2021215801A1 (ko) *	2020-04-20	2021-10-28	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
AU2021278157A1 (en) *	2020-05-29	2022-11-24	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Dual-agonist compound for both GLP-1 and GIP receptors and application thereof
AU2021304762B2 (en) *	2020-07-06	2024-05-02	Vitalixir (Beijing) Co., Ltd	Novel polypeptide and therapeutic use thereof
WO2022007809A1 (zh) *	2020-07-06	2022-01-13	鸿绪生物医药科技（北京）有限公司	新型多肽制剂及其治疗用途
MX2023000303A (es)	2020-07-22	2023-02-09	Novo Nordisk As	Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
KR20230042019A (ko)	2020-07-22	2023-03-27	노보 노르디스크 에이/에스	Glp-1 및 gip 수용체 공동-작용제
BR112023002608A2 (pt) *	2020-08-12	2023-05-09	Txp Pharma Ag	Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade
JP2023550594A (ja)	2020-10-30	2023-12-04	ノヴォノルディスクアー／エス	Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬
CN114617956B (zh) *	2020-12-10	2023-10-03	江苏中新医药有限公司	一种高效降糖的蛋白质药物
AU2022245736A1 (en) *	2021-03-25	2023-10-12	Brightgene Bio-Medical Technology Co., Ltd.	Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
WO2022247701A1 (zh)	2021-05-26	2022-12-01	联邦生物科技(珠海横琴)有限公司	多激动剂及其应用
MX2023015068A (es) *	2021-06-18	2024-01-17	Beijing Tuo Jie Biopharmaceutical Co Ltd	Analogo de glucagon y uso medico del mismo.
WO2022268029A1 (zh) *	2021-06-21	2022-12-29	广东东阳光药业有限公司	Glp-1、gcg和gip受体的三重激动剂
TW202313667A (zh) *	2021-07-30	2023-04-01	大陸商南京明德新藥研發有限公司	含內醯胺橋的多肽化合物
US20240360194A1 (en)	2021-09-06	2024-10-31	Sanofi	New Peptides as Potent and Selective GIP Receptor Agonists
KR20240109258A (ko) *	2021-11-12	2024-07-10	푸지엔 셩디 파마슈티컬 컴파니 리미티드	Glp-1 수용체와 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
CN118234742A (zh) *	2021-12-01	2024-06-21	江苏恒瑞医药股份有限公司	Glp-1和gip受体双重激动剂的药物组合物及其用途
TW202330584A (zh)	2022-01-20	2023-08-01	丹麥商諾佛儂迪克股份有限公司	前藥及其用途
CN117603364A (zh) *	2022-09-30	2024-02-27	广西医科大学附属肿瘤医院	一类GLP-1/glucagon/Y2受体三重激动剂及其应用
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
GB2642930A (en) *	2023-02-24	2026-01-28	Ip2Ipo Innovations Ltd	Compounds
GB202302686D0 (en) *	2023-02-24	2023-04-12	Imperial College Innovations Ltd	Novel compounds
TW202502808A (zh) *	2023-07-14	2025-01-16	大陸商北京拓界生物醫藥科技有限公司	Glp-1、gip和gcg受體三激動劑及其應用
CN120329412A (zh) *	2023-11-06	2025-07-18	成都奥达生物科技有限公司	一种三激动剂化合物
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025162423A1 (zh) *	2024-02-02	2025-08-07	杭州先为达生物科技股份有限公司	针对glp-1r、gipr和gcgr的三激动剂
WO2025176999A2 (en) *	2024-02-23	2025-08-28	Ip2Ipo Innovations Limited	Novel compounds
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025219590A1 (en)	2024-04-19	2025-10-23	Actimed Therapeutics Ltd	Beta-blockers for preserving muscle mass, bone density, and cardiac function in weight loss treatments
CN119390784A (zh) *	2024-07-11	2025-02-07	中国药科大学	一种双激动多肽化合物及其医药用途

Family Cites Families (437)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5641757A (en)	1994-12-21	1997-06-24	Ortho Pharmaceutical Corporation	Stable 2-chloro-2'-deoxyadenosine formulations
ATE417622T1 (de)	1996-08-08	2009-01-15	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
KR100556067B1 (ko)	1996-08-30	2006-03-07	노보 노르디스크 에이/에스	지엘피 - 1 유도체
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
AU739020B2 (en)	1997-01-07	2001-10-04	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the reduction of food intake
US7312196B2 (en)	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6410511B2 (en)	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6723530B1 (en)	1997-02-05	2004-04-20	Amylin Pharmaceuticals, Inc.	Polynucleotides encoding proexendin, and methods and uses thereof
US7157555B1 (en)	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
PT1019077E (pt)	1997-08-08	2008-02-21	Amylin Pharmaceuticals Inc	Novos compostos agonistas de exendina
DE69838916T2 (de)	1997-11-14	2008-12-18	Amylin Pharmaceuticals, Inc., San Diego	Neuartige exendin agonisten
US7223725B1 (en)	1997-11-14	2007-05-29	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
US7220721B1 (en)	1997-11-14	2007-05-22	Amylin Pharmaceuticals, Inc.	Exendin agonist peptides
EP1032587B2 (en)	1997-11-14	2013-03-13	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
JP4353544B2 (ja)	1998-01-09	2009-10-28	アミリン・ファーマシューティカルズ，インコーポレイテッド	アミリン作動薬ペプチド用製剤
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
EP1056775B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
NZ506839A (en)	1998-03-09	2003-05-30	Zealand Pharma As	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO1999047160A1 (en)	1998-03-13	1999-09-23	Novo Nordisk A/S	Stabilized aqueous peptide solutions
US6998387B1 (en)	1998-03-19	2006-02-14	Amylin Pharmaceuticals, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
CZ294848B6 (cs)	1998-06-12	2005-03-16	Amylin Pharmaceuticals, Inc.	Glukagonu podobný peptid-1 zlepšuje odpověď ß-buněk na glukózu u subjektů se zhoršenou tolerancí glukózy
DE69941510D1 (de)	1998-08-10	2009-11-19	Us Gov Nat Inst Health	Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
CN1317967A (zh)	1998-09-17	2001-10-17	伊莱利利公司	蛋白质制剂
US7259136B2 (en)	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
DK1140148T3 (da)	1998-12-22	2006-01-30	Lilly Co Eli	Lagerholdbar formulering af glucagon-agtigt peptid-1
US7399489B2 (en)	1999-01-14	2008-07-15	Amylin Pharmaceuticals, Inc.	Exendin analog formulations
PT1140145E (pt)	1999-01-14	2005-11-30	Amylin Pharmaceuticals Inc	Formulacoes novas de agonistas de exendina e metodos para a sua administracao
NZ512657A (en)	1999-01-14	2004-01-30	Amylin Pharmaceuticals Inc	Glucagon suppression
US20030087820A1 (en)	1999-01-14	2003-05-08	Young Andrew A.	Novel exendin agonist formulations and methods of administration thereof
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
CA2361830A1 (en)	1999-03-17	2000-09-21	Novo Nordisk A/S	Method for acylating peptides and novel acylating agents
WO2000066629A1 (en)	1999-04-30	2000-11-09	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6887470B1 (en)	1999-09-10	2005-05-03	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
SI1180121T1 (en)	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
US6849714B1 (en)	1999-05-17	2005-02-01	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6482799B1 (en)	1999-05-25	2002-11-19	The Regents Of The University Of California	Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6506724B1 (en)	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6972319B1 (en)	1999-09-28	2005-12-06	Bayer Pharmaceuticals Corporation	Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
CA2396157A1 (en)	2000-01-10	2001-07-19	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
AU2001252201A1 (en)	2000-03-14	2001-09-24	Amylin Pharmaceuticals, Inc.	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
WO2001087322A2 (en)	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
KR100518046B1 (ko)	2000-05-19	2005-10-04	아밀린 파마슈티칼스, 인크.	Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
WO2002016309A1 (en)	2000-08-18	2002-02-28	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US7507714B2 (en)	2000-09-27	2009-03-24	Bayer Corporation	Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
WO2002034285A2 (en)	2000-10-20	2002-05-02	Coolidge Thomas R	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
BR0116024A (pt)	2000-12-07	2005-12-13	Lilly Co Eli	Proteìna de fusão heteróloga e uso da mesma
US7259233B2 (en)	2000-12-13	2007-08-21	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
GB2371227A (en)	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
CN1162446C (zh)	2001-05-10	2004-08-18	上海华谊生物技术有限公司	促胰岛素分泌肽衍生物
AU2002308706A1 (en)	2001-06-01	2002-12-16	Eli Lilly And Company	Glp-1 formulations with protracted time action
ATE382057T1 (de)	2001-06-28	2008-01-15	Novo Nordisk As	Stabile formulierung von modifiziertem glp-1
ES2320431T3 (es)	2001-07-16	2009-05-22	Caprotec Bioanalytics Gmbh	Compuestos de captura, colecciones de los mismos y metodos para analizar el proteoma y composiciones complejas.
DE60228972D1 (de)	2001-07-31	2008-10-30	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
US7238663B2 (en)	2001-08-28	2007-07-03	Eli Lilly And Company	Pre-mixes of GLP-1 and basal insulin
CN1571676A (zh)	2001-10-19	2005-01-26	伊莱利利公司	Glp－1和胰岛素的双相混合物
EP2277889B1 (en)	2001-12-21	2014-07-09	Human Genome Sciences, Inc.	Fusion proteins of albumin and interferon beta
CA2484556A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US7105489B2 (en)	2002-01-22	2006-09-12	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
JP4417113B2 (ja)	2002-02-20	2010-02-17	エミスフェアー・テクノロジーズ・インク	Ｇｌｐ−１分子の投与方法
PT1946776T (pt)	2002-02-27	2017-03-17	Immunex Corp	Composição de tnfr-fc estabilizada compreendendo arginina
WO2003077851A2 (en)	2002-03-11	2003-09-25	Hk Pharmaceuticals, Inc.	Compounds and methods for analyzing the proteome
US7141240B2 (en)	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
JP2005535569A (ja)	2002-04-04	2005-11-24	ノボ・ノルデイスク・エー／エス	Ｇｌｐ−１アゴニスト及び心臓血管合併症
EA200401345A1 (ru)	2002-04-10	2005-08-25	Эли Лилли Энд Компани	Лечение гастропареза
US6861236B2 (en)	2002-05-24	2005-03-01	Applied Nanosystems B.V.	Export and modification of (poly)peptides in the lantibiotic way
AU2003232172A1 (en)	2002-06-14	2003-12-31	Novo Nordisk A/S	Combined use of a modulator of cd3 and a glp-1 compound
US20040037826A1 (en)	2002-06-14	2004-02-26	Michelsen Birgitte Koch	Combined use of a modulator of CD3 and a GLP-1 compound
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
ATE432289T1 (de)	2002-07-04	2009-06-15	Zealand Pharma As	Glp-1 und behandlungsmethode für diabetes
WO2004004780A1 (en)	2002-07-09	2004-01-15	Sandoz Ag	Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20070065469A1 (en)	2002-07-09	2007-03-22	Michael Betz	Liquid formulations with high concentration of human growth hormone (high) comprising glycine
US20040038865A1 (en)	2002-08-01	2004-02-26	Mannkind Corporation	Cell transport compositions and uses thereof
US20080260838A1 (en)	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
AU2003257156B2 (en)	2002-08-01	2007-08-30	Mannkind Corporation	Cell transport compositions and uses thereof
EA016166B1 (ru)	2002-08-21	2012-02-28	Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг	8-[3-аминопиперидин-1-ил]ксантины, способ их получения и их применение в качестве лекарственных средств
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003268621B2 (en)	2002-10-02	2009-01-15	Zealand Pharma A/S	Stabilized exendin-4 compounds
US20050209142A1 (en)	2002-11-20	2005-09-22	Goran Bertilsson	Compounds and methods for increasing neurogenesis
ATE494904T1 (de)	2002-11-20	2011-01-15	Neuronova Ab	Verbindungen und verfahren zur erhöhung der neurogenese
US6969702B2 (en)	2002-11-20	2005-11-29	Neuronova Ab	Compounds and methods for increasing neurogenesis
US20040209803A1 (en)	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006514035A (ja)	2002-12-17	2006-04-27	アミリン・ファーマシューティカルズ，インコーポレイテッド	心不整脈の予防および治療
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
WO2004089280A2 (en)	2003-04-08	2004-10-21	Yeda Research And Development Co. Ltd.	Reversible pegylated drugs
WO2004089985A1 (en)	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
ATE549028T1 (de)	2003-05-15	2012-03-15	Tufts College	Stabile analoga von glp-1
US7947261B2 (en)	2003-05-23	2011-05-24	Nektar Therapeutics	Conjugates formed from polymer derivatives having particular atom arrangements
HUE043911T2 (hu)	2003-05-23	2019-09-30	Nektar Therapeutics	Két PEG láncot tartalmazó PEG származékok
ES2425221T3 (es)	2003-05-30	2013-10-14	Amylin Pharmaceuticals, Llc	Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
PL1633391T3 (pl)	2003-06-03	2012-03-30	Novo Nordisk As	Stabilizowane farmaceutycznie kompozycje peptydowe
WO2004105781A2 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
ES2375056T3 (es)	2003-06-03	2012-02-24	Novo Nordisk A/S	Composiciones pept�?dicas farmacéuticas estabilizadas.
KR101308912B1 (ko)	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
US8921311B2 (en)	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
EP2107069B1 (en)	2003-08-05	2013-01-16	Novo Nordisk A/S	Novel insulin derivatives
AU2004266757A1 (en)	2003-08-21	2005-03-03	Novo Nordisk A/S	Separation of polypeptides comprising a racemized amino acid
US20060247167A1 (en)	2003-09-01	2006-11-02	Novo Nordisk A/S	Stable formulations of peptides
EP1663295A2 (en)	2003-09-01	2006-06-07	Novo Nordisk A/S	Stable formulations of peptides
JP2007537981A (ja)	2003-09-19	2007-12-27	ノボ　ノルディスク　アクティーゼルスカブ	新規の血漿タンパク質親和性タグ
EP1684793B1 (en)	2003-11-13	2011-09-21	Novo Nordisk A/S	Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
US20050106214A1 (en)	2003-11-14	2005-05-19	Guohua Chen	Excipients in drug delivery vehicles
US20050281879A1 (en)	2003-11-14	2005-12-22	Guohua Chen	Excipients in drug delivery vehicles
SI3300721T2 (sl)	2003-11-20	2025-05-30	Novo Nordisk A/S	Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje
EP1750752A2 (en)	2003-11-20	2007-02-14	Neuronova AB	Compounds and methods for increasing neurogenesis
ATE517119T1 (de)	2003-12-03	2011-08-15	Novo Nordisk As	Einzelketteninsulin
AU2004298996A1 (en)	2003-12-10	2005-06-30	Nektar Therapeutics Al, Corporation	Compositions comprising two different populations of polymer-active agent conjugates
US20060210614A1 (en)	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en)	2003-12-26	2005-06-30	Nastech Pharmaceutical Company Inc.	Intranasal administration of glucose-regulating peptides
CN1938334A (zh) *	2004-01-30	2007-03-28	瓦拉塔药品公司	Glp－1激动剂和胃泌素化合物的联合使用
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
EP1789440A4 (en)	2004-02-11	2008-03-12	Amylin Pharmaceuticals Inc	REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
EP2233497A3 (en)	2004-02-11	2011-01-12	Amylin Pharmaceuticals, Inc.	Amylin family peptides and methods for making and using them
EP2422806A3 (en)	2004-02-11	2012-06-13	Amylin Pharmaceuticals Inc.	Hybrid polypeptides with selectable properties
US7399744B2 (en)	2004-03-04	2008-07-15	Amylin Pharmaceuticals, Inc.	Methods for affecting body composition
US20060110423A1 (en)	2004-04-15	2006-05-25	Wright Steven G	Polymer-based sustained release device
KR101040415B1 (ko)	2004-04-15	2011-06-09	알케르메스,인코포레이티드	중합체 기재 지속적 방출 방법
US7456254B2 (en)	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
US20090069226A1 (en)	2004-05-28	2009-03-12	Amylin Pharmaceuticals, Inc.	Transmucosal delivery of peptides and proteins
WO2005117584A2 (en)	2004-05-28	2005-12-15	Amylin Pharmaceuticals, Inc	Improved transmucosal delivery of peptides and proteins
EP2316446A1 (en)	2004-06-11	2011-05-04	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
US7872095B2 (en)	2004-07-19	2011-01-18	Biocon Limited	Insulin-oligomer conjugates, formulations and uses thereof
WO2006091231A2 (en)	2004-07-21	2006-08-31	Ambrx, Inc.	Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EA200700391A1 (ru)	2004-08-03	2007-10-26	Байорексис Текнолоджи, Инк.	Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
US20070204633A1 (en)	2004-08-16	2007-09-06	Whisson Maxwell E	Apparatus and Method for Cooling of Air
PL1789434T3 (pl)	2004-08-31	2014-07-31	Novo Nordisk As	Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
DE102004043153B4 (de)	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
WO2006028110A1 (ja)	2004-09-07	2006-03-16	Chugai Seiyaku Kabushiki Kaisha	水溶性ヒアルロン酸修飾物の製造方法
US20080280814A1 (en)	2004-09-17	2008-11-13	Novo Nordisk A/S	Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
MX366832B (es)	2004-10-01	2019-07-24	Ramscor Inc	Composiciones de farmaco de liberacion sostenida convenientemente implantables.
JP5107713B2 (ja)	2004-10-07	2012-12-26	ノヴォノルディスクアー／エス	遅延性のエキセンディン−４化合物
US7595294B2 (en)	2004-10-08	2009-09-29	Transition Therapeutics, Inc.	Vasoactive intestinal polypeptide pharmaceuticals
US20060089325A1 (en)	2004-10-13	2006-04-27	Sanjay Bhanot	Antisense modulation of PTP1B expression
US7442682B2 (en)	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
ES2458991T5 (en)	2004-11-12	2025-10-14	Novo Nordisk As	Stable formulations of insulinoptropic peptides
US20080125361A1 (en)	2004-11-12	2008-05-29	Novo Nordisk A/S	Stable Formulations Of Peptides
US20090011976A1 (en)	2004-11-12	2009-01-08	Novo Nordisk A/S	Stable Formulations Of Peptides
RU2428431C2 (ru)	2004-12-02	2011-09-10	Домантис Лимитед	Слитые конструкции лекарственного средства и конъюгаты
MX2007006830A (es)	2004-12-13	2008-02-07	Amylin Pharmaceuticals Inc	Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
EP1827501B2 (en)	2004-12-21	2013-11-20	Nektar Therapeutics	Stabilized polymeric thiol reagents
ATE435235T1 (de)	2004-12-22	2009-07-15	Lilly Co Eli	Formulierungen glp-1-analoger fusionsproteine
EP1838336A2 (en)	2004-12-24	2007-10-03	Amylin Pharmaceuticals, Inc.	Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
US8716221B2 (en)	2005-01-14	2014-05-06	Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.	Modified exendins and uses thereof
CN100540565C (zh)	2005-01-14	2009-09-16	无锡宏创医药科技有限公司	修饰的Exendins及其应用
WO2006082588A2 (en)	2005-02-07	2006-08-10	Pharmalight Inc.	Method and device for ophthalmic administration of active pharmaceutical ingredients
CA2597649A1 (en)	2005-02-11	2006-08-17	Amylin Pharmaceuticals, Inc.	Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
WO2006097535A2 (en)	2005-03-18	2006-09-21	Novo Nordisk A/S	Peptide agonists of the glucagon family with secretin like activity
DK1888103T3 (da)	2005-04-11	2012-04-23	Amylin Pharmaceuticals Inc	Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
JP4979686B2 (ja)	2005-04-24	2012-07-18	ノボ・ノルデイスク・エー／エス	注入デバイス
CN101180081B (zh)	2005-05-25	2015-08-26	诺沃-诺迪斯克有限公司	稳定的多肽制剂
CN101282991A (zh)	2005-05-26	2008-10-08	布里斯托尔-迈尔斯斯奎布公司	N-端修饰的胰高血糖素样肽-1受体调节剂
CA2609810C (en)	2005-06-06	2012-05-22	Camurus Ab	Glp-1 analogue formulations
JP2008543816A (ja)	2005-06-13	2008-12-04	インペリアルイノベーションズリミテッド	新規化合物および該化合物が摂食行動に及ぼす効果
GB0511986D0 (en)	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
MX2007016314A (es)	2005-06-16	2008-03-10	Nektar Therapeutics Al Corp	Conjugados que tienen un enlace degradable y reactivos polimericos utiles en la preparacion de tales conjugados.
WO2007019331A2 (en)	2005-08-04	2007-02-15	Nektar Therapeutics Al, Corporation	Conjugates of a g-csf moiety and a polymer
CN101277722A (zh)	2005-08-06	2008-10-01	王庆华	用于预防和治疗ⅰ型糖尿病的组合物及方法
AU2006279680B2 (en)	2005-08-11	2012-12-06	Amylin Pharmaceuticals, Llc	Hybrid polypeptides with selectable properties
DK2347762T3 (da)	2005-08-19	2019-06-11	Amylin Pharmaceuticals Llc	Exendin til behandling af diabetes og reduktion af kropsvægt
US7799344B2 (en)	2005-09-14	2010-09-21	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
JP5072848B2 (ja)	2005-09-20	2012-11-14	ノバルティスアーゲー	低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
WO2007047834A2 (en)	2005-10-18	2007-04-26	Biocon Limited	Oral peptide conjugates for metabolic diseases
US20070099820A1 (en)	2005-10-19	2007-05-03	Smartcells, Inc.	Polymer-drug conjugates
WO2007056362A2 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
WO2007053946A1 (en)	2005-11-09	2007-05-18	Conjuchem Biotechnologies Inc.	Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
US8293726B2 (en)	2005-12-02	2012-10-23	Vianova Labs, Inc.	Treatment of cancer and other diseases
MX2008007075A (es)	2005-12-02	2008-11-12	Mdrna Inc	Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.
WO2007067964A2 (en)	2005-12-08	2007-06-14	Nastech Pharmaceutical Company Inc.	Mucosal delivery of stabilized formulations of exendin
JP5096363B2 (ja)	2005-12-16	2012-12-12	ネクターセラピューティックス	Ｇｌｐ−１のポリマ複合体
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1971355B1 (en)	2005-12-20	2020-03-11	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
ES2397712T3 (es)	2006-01-18	2013-03-08	Qps, Llc	Composiciones farmacéuticas con estabilidad reforzada
AU2007212147A1 (en)	2006-02-03	2007-08-16	Medimmune, Llc	Protein formulations
US7704953B2 (en)	2006-02-17	2010-04-27	Mdrna, Inc.	Phage displayed cell binding peptides
JP5412273B2 (ja)	2006-03-21	2014-02-12	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	ペプチド−ぺプチダーゼ阻害剤及びその使用
CA2648440A1 (en)	2006-04-13	2007-10-25	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. .	Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
RU2409349C2 (ru)	2006-04-14	2011-01-20	Маннкайнд Корпорейшн	Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2029160A2 (en)	2006-05-12	2009-03-04	Amylin Pharmaceuticals, Inc.	Methods to restore glycemic control
WO2007139589A1 (en)	2006-05-26	2007-12-06	Bristol-Myers Squibb Company	Sustained release glp-1 receptor modulators
EP2636680A3 (en)	2006-05-26	2013-12-11	Amylin Pharmaceuticals, LLC	Composition and methods for treatment of congestive heart failure
PT2038423E (pt)	2006-06-21	2013-03-27	Biocon Ltd	Método de produção de um polipéptido biologicamente activo possuindo actividade insulinotrópica
DK2494959T3 (en)	2006-07-05	2015-02-23	Foamix Pharmaceuticals Ltd	Foam Bart dicarboxylsyrebærestof and pharmaceutical compositions thereof
CA2658654A1 (en)	2006-07-24	2008-01-31	Biorexis Pharmaceutical Corporation	Exendin fusion proteins
US7928186B2 (en)	2006-08-02	2011-04-19	Phoenix Pharmaceuticals, Inc.	Cell permeable bioactive peptide conjugates
EP2046284A1 (en)	2006-08-04	2009-04-15	Nastech Pharmaceutical Company Inc.	Compositions for intranasal delivery of human insulin and uses thereof
AU2007284759B2 (en)	2006-08-09	2010-10-28	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2660835A1 (en)	2006-08-17	2008-02-21	Amylin Pharmaceuticals, Inc.	Dpp-iv resistant gip hybrid polypeptides with selectable propperties
US20090318353A1 (en) *	2006-08-25	2009-12-24	Novo Nordisk A/S	Acylated Exendin-4 Compounds
CN102827284B (zh)	2006-11-14	2015-07-29	上海仁会生物制药股份有限公司	带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
JP2010512399A (ja)	2006-12-12	2010-04-22	アミリン・ファーマシューティカルズ，インコーポレイテッド	医薬製剤及びその調製方法
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
RU2432361C2 (ru)	2007-01-05	2011-10-27	КовЭкс Текнолоджиз Айэлэнд Лимитед	Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
CN101663317A (zh) *	2007-01-05	2010-03-03	CovX科技爱尔兰有限公司	胰高血糖素样蛋白-1受体glp-1r激动剂化合物
US20090098130A1 (en) *	2007-01-05	2009-04-16	Bradshaw Curt W	Glucagon-like protein-1 receptor (glp-1r) agonist compounds
EP2124974B1 (en)	2007-01-05	2017-03-15	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
WO2008098212A2 (en)	2007-02-08	2008-08-14	Diobex, Inc.	Extended release formulations of glucagon and other peptides and proteins
AU2008216265B2 (en)	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
WO2008130066A1 (en)	2007-04-20	2008-10-30	Kang Choon Lee	Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
CN101715340A (zh)	2007-04-23	2010-05-26	精达制药公司	促胰岛素释放肽的混悬制剂及其应用
US8236760B2 (en)	2007-04-27	2012-08-07	Cedars-Sinsai Medical Center	Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
US7829664B2 (en)	2007-06-01	2010-11-09	Boehringer Ingelheim International Gmbh	Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
CA2689909C (en)	2007-06-08	2016-04-05	Ascendis Pharma As	Long-acting polymeric prodrugs of exendin
US7994122B2 (en)	2007-06-15	2011-08-09	Zealand Pharma A/S	Glucagon analogues
US20100196405A1 (en)	2007-07-10	2010-08-05	Kingman Ng	GLP-1 Fc FUSION PROTEIN FORMULATION
EP2185178B1 (en)	2007-08-03	2017-08-23	Eli Lilly And Company	Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN101366692A (zh)	2007-08-15	2009-02-18	江苏豪森药业股份有限公司	一种稳定的艾塞那肽制剂
MY165889A (en)	2007-08-30	2018-05-18	Curedm Group Holdings Llc	Compositions and methods of using proislet peptides and analogs thereof
ES2532116T3 (es)	2007-09-05	2015-03-24	Novo Nordisk A/S	Péptidos derivados con A-B-C-D y sus usos terapéuticos
JP2010538069A (ja)	2007-09-07	2010-12-09	イプセンファルマソシエテパールアクシオンサンプリフィエ	エキセンディン−４およびエキセンディン−３の類似体
CA2703338A1 (en)	2007-10-24	2009-04-30	Mannkind Corporation	Method of preventing adverse effects by glp-1
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
BRPI0818874A2 (pt)	2007-10-24	2015-05-05	Mannkind Corp	Liberação de agentes ativos
JP5669582B2 (ja)	2007-10-30	2015-02-12	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴンアンタゴニスト
EP2214691B1 (en)	2007-10-30	2015-09-30	Indiana University Research and Technology Corporation	Compounds exhibiting glucagon antagonist and glp-1 agonist activity
MX2010005245A (es)	2007-11-16	2010-06-01	Novo Nordisk As	Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
EP2224945B1 (en)	2007-11-23	2012-05-16	Michael Rothkopf	Methods of enhancing diabetes resolution
CN101444618B (zh)	2007-11-26	2012-06-13	杭州九源基因工程有限公司	含有艾塞那肽的药物制剂
JP2011506442A (ja)	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	インスリン分泌性ペプチド結合体の製剤
EP2229407B1 (de)	2008-01-09	2016-11-16	Sanofi-Aventis Deutschland GmbH	Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
AU2009210570B2 (en)	2008-01-30	2014-11-20	Indiana University Research And Technology Corporation	Ester-based insulin prodrugs
HRP20191052T1 (hr)	2008-02-01	2019-11-01	Ascendis Pharma As	Predlijek koji obuhvaća samocijepajuću poveznicu
EP2247737B1 (en)	2008-02-06	2018-06-20	Biocon Limited	Fermentation medias and processes thereof
WO2009114959A1 (zh)	2008-03-20	2009-09-24	中国人民解放军军事医学科学院毒物药物研究所	可注射用缓释药物制剂及其制备方法
CA2720864C (en)	2008-04-07	2017-07-04	National Institute Of Immunology	Compositions useful for the treatment of diabetes and other chronic disorder
JP5671451B2 (ja)	2008-05-07	2015-02-18	メリオン・リサーチ・Ｉｉｉ・リミテッド	ＧｎＲＨ関連化合物の組成物および調製プロセス
US20110263496A1 (en)	2008-05-21	2011-10-27	Amylin Pharmaceuticals, Inc.	Exendins to lower cholesterol and triglycerides
WO2009143014A1 (en)	2008-05-23	2009-11-26	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonist bioassays
DK2293833T3 (en)	2008-06-13	2016-05-23	Mannkind Corp	DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
MX337038B (es)	2008-06-17	2016-02-10	Univ Indiana Res & Tech Corp	Co-antagonistas de receptor de glucagon/glp-1.
CN104447980A (zh)	2008-06-17	2015-03-25	印第安纳大学研究及科技有限公司	在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
EP2300035B1 (en)	2008-06-17	2015-08-12	Indiana University Research and Technology Corporation	Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP5604297B2 (ja)	2008-06-17	2014-10-08	株式会社糖鎖工学研究所	糖鎖付加ｇｌｐ−１ペプチド
WO2009158704A2 (en)	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
US20110129522A1 (en)	2008-07-21	2011-06-02	Transpharma Medical Ltd.	Transdermal system for extended delivery of incretins and incretn mimetic peptides
WO2010013012A2 (en)	2008-08-01	2010-02-04	Lund University Bioscience Ab	Novel polypeptides and uses thereof
CN101670096B (zh)	2008-09-11	2013-01-16	杭州九源基因工程有限公司	含有艾塞那肽的药物制剂
PT2349324T (pt)	2008-10-17	2017-12-06	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
EP2373681B1 (en)	2008-12-10	2017-01-18	Glaxosmithkline LLC	Pharmaceutical compositions of albiglutide
KR20110126592A (ko)	2008-12-15	2011-11-23	질랜드 파마 에이/에스	글루카곤 유사체
EP2370462B1 (en)	2008-12-15	2014-07-16	Zealand Pharma A/S	Glucagon analogues
AU2008365555B2 (en)	2008-12-15	2016-01-14	Zealand Pharma A/S	Glucagon analogues
MX2011006320A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
SG172291A1 (en)	2008-12-19	2011-07-28	Univ Indiana Res & Tech Corp	Amide based glucagon superfamily peptide prodrugs
CN101538323B (zh)	2009-01-13	2012-05-09	深圳翰宇药业股份有限公司	一种纯化艾塞那肽的方法
DE102009006602A1 (de)	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
AU2010221254B2 (en)	2009-03-04	2014-04-03	Mannkind Corporation	An improved dry powder drug delivery system
WO2010100241A1 (en)	2009-03-05	2010-09-10	Sanofi-Aventis Deutschland Gmbh	Drug delivery device with retractable needle
EP2413955A4 (en)	2009-04-01	2012-12-26	Amylin Pharmaceuticals Inc	N-TERMINAL CONFORMATION RESTRICTED GLP-1 RECEPTOR AGONIST COMPOUNDS
US8992886B2 (en)	2009-04-06	2015-03-31	Board Of Regents, The University Of Texas System	Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
US9012606B2 (en)	2009-04-22	2015-04-21	Alteogen, Inc.	In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same
CN101870728A (zh)	2009-04-23	2010-10-27	派格生物医药(苏州)有限公司	新型Exendin变体及其缀合物
CN101559041B (zh)	2009-05-19	2014-01-15	中国科学院过程工程研究所	粒径均一的多肽药物缓释微球或微囊制剂及制备方法
CN105536110B (zh)	2009-05-20	2020-01-17	赛诺菲-安万特德国有限公司	用于药物递送装置中药物容纳筒的塞子
WO2010133676A1 (en)	2009-05-20	2010-11-25	Sanofi-Aventis Deutschland Gmbh	A system comprising a drug delivery device and a cartridge provided with a bung and a method of identifying the cartridge
EP2435061A4 (en)	2009-05-28	2013-03-27	Amylin Pharmaceuticals Inc	DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
CN102802657A (zh)	2009-06-11	2012-11-28	诺沃-诺迪斯克有限公司	用于治疗2型糖尿病的glp-1和fgf21组合
MX2011013625A (es)	2009-06-16	2012-01-20	Univ Indiana Res & Tech Corp	Compuestos glucagon activo de receptor de gip.
JP5932642B2 (ja)	2009-07-02	2016-06-08	アンジオケムインコーポレーテッド	多量体ペプチドコンジュゲートおよびその使用
AP3329A (en)	2009-07-13	2015-06-30	Zealand Pharma As	Acylated glucagon analogues
CN101601646B (zh)	2009-07-22	2011-03-23	南京凯瑞尔纳米生物技术有限公司	治疗糖尿病的鼻腔滴剂及其制备方法
WO2011011675A1 (en)	2009-07-23	2011-01-27	Zelos Therapeutics, Inc.	Pharmaceutically acceptable formulations/compositions for peptidyl drugs
PE20120918A1 (es)	2009-07-31	2012-08-14	Sanofi Aventis Deutschland	Profarmacos que comprenden un conjugado de insulina-conector
WO2011017835A1 (en)	2009-08-11	2011-02-17	Nanjing University	Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
CN101993485B (zh)	2009-08-20	2013-04-17	重庆富进生物医药有限公司	促胰岛素分泌肽类似物同源二聚体及其用途
US20120148586A1 (en)	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
MX2012003939A (es)	2009-09-30	2012-07-30	Glaxo Group Ltd	Fusiones y conjugados de farmaco.
DK2490708T3 (da)	2009-10-22	2013-04-15	Biodel Inc	Stabiliserede glucagon-opløsninger
US20110097386A1 (en)	2009-10-22	2011-04-28	Biodel, Inc.	Stabilized glucagon solutions
US9610329B2 (en)	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
EP2495255A4 (en)	2009-10-30	2013-05-15	Otsuka Chemical Co Ltd	GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG
KR101426180B1 (ko)	2009-11-02	2014-07-31	화이자 인코포레이티드	디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
WO2011056713A2 (en)	2009-11-03	2011-05-12	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2011058083A1 (de)	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
RU2012130011A (ru)	2009-12-15	2014-01-27	МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи	Ppar-снижающие тиазолидиндионы и комбинации для лечения сахарного диабета и других нарушений обмена веществ
AU2010340061A1 (en)	2009-12-15	2012-06-21	Metabolic Solutions Development Company, Llc	PPAR-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
JP2013514368A (ja)	2009-12-15	2013-04-25	メタボリックソリューションズディベロップメントカンパニー，エルエルシー	神経変性疾患を処置するための、ｐｐａｒ温存チアゾリジンジオンおよび組み合わせ物
HUE038042T2 (hu)	2009-12-15	2018-09-28	Cirius Therapeutics Inc	PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
MX2012006634A (es)	2009-12-16	2012-06-21	Novo Nordisk As	Derivados de peptidos tipo glucagon 1 de doble acilato.
CN102933200B (zh)	2009-12-18	2015-11-25	莱迪杜德制药公司	包含磷脂的单相凝胶组合物
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
CN101798588B (zh) *	2009-12-21	2015-09-09	上海仁会生物制药股份有限公司	Glp-1受体激动剂生物学活性测定方法
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina
AU2011206979B2 (en)	2010-01-20	2015-09-10	Zealand Pharma A/S	Treatment of cardiac conditions
JP2013518115A (ja)	2010-01-27	2013-05-20	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーション	代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
US9775949B2 (en)	2010-02-01	2017-10-03	Sanofi-Aventis Deutschland Gmbh	Cartridge holder, drug delivery device and method for securing a cartridge in a cartridge holder
WO2011109784A1 (en)	2010-03-05	2011-09-09	Conjuchem, Llc	Formulation of insulinotropic peptide conjugates
US8840601B2 (en)	2010-03-24	2014-09-23	Shifamed Holdings, Llc	Intravascular tissue disruption
AR080592A1 (es) *	2010-03-26	2012-04-18	Lilly Co Eli	Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
RU2559320C2 (ru)	2010-03-26	2015-08-10	Ново Нордиск А/С	Новые аналоги глюкагона
RU2012153753A (ru)	2010-05-13	2014-06-20	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
ES2661228T3 (es)	2010-05-13	2018-03-28	Indiana University Research And Technology Corporation	Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
EP2571900A1 (en)	2010-05-20	2013-03-27	Glaxo Group Limited	Improved anti-serum albumin binding variants
WO2011156407A2 (en)	2010-06-09	2011-12-15	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonists to treat pancre-atitis
CN101891823B (zh)	2010-06-11	2012-10-03	北京东方百泰生物科技有限公司	一种Exendin-4及其类似物融合蛋白
US8636711B2 (en)	2010-06-14	2014-01-28	Legacy Emanuel Hospital & Health Center	Stabilized glucagon solutions and uses therefor
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
US9234023B2 (en)	2010-06-24	2016-01-12	Biousian Biosystems, Inc.	Glucagon-like peptide-1 glycopeptides
CA2796894A1 (en)	2010-06-24	2011-12-29	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
WO2011163473A1 (en)	2010-06-25	2011-12-29	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
US20130137645A1 (en)	2010-07-19	2013-05-30	Mary S. Rosendahl	Modified peptides and proteins
US20120046225A1 (en)	2010-07-19	2012-02-23	The Regents Of The University Of Colorado, A Body Corporate	Stable glucagon formulations for the treatment of hypoglycemia
EA201390182A1 (ru)	2010-07-28	2014-01-30	АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
CN102397558B (zh)	2010-09-09	2013-08-14	中国人民解放军军事医学科学院毒物药物研究所	Exendin-4类似物的定位聚乙二醇化修饰物及其用途
EP2438930A1 (en)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Prodrugs comprising an exendin linker conjugate
CN106986940A (zh)	2010-09-28	2017-07-28	艾米琳制药有限责任公司	具有增强的作用持续时间的工程化多肽
WO2012059762A1 (en)	2010-11-03	2012-05-10	Arecor Limited	Novel composition comprising glucagon
CN107854454A (zh)	2010-11-09	2018-03-30	曼金德公司	用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
EP2460552A1 (en)	2010-12-06	2012-06-06	Sanofi-Aventis Deutschland GmbH	Drug delivery device with locking arrangement for dose button
CN102552883B (zh)	2010-12-09	2014-02-19	天津药物研究院	一种多肽复合物、药物组合物、其制备方法和应用
RS56998B1 (sr)	2010-12-16	2018-05-31	Novo Nordisk As	Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
WO2012088157A2 (en)	2010-12-22	2012-06-28	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonists for islet cell transplantation
EA201390941A1 (ru)	2010-12-22	2013-12-30	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Аналоги глюкагона, проявляющие активность на рецепторе gip
CN102532301B (zh)	2010-12-31	2014-09-03	上海医药工业研究院	一类新型的Exendin-4类似物及其制备方法
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102100906A (zh)	2011-02-18	2011-06-22	深圳翰宇药业股份有限公司	一种艾塞那肽的药用制剂及其制备方法
AU2012225268B2 (en)	2011-03-10	2016-10-20	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of peptide drugs
CN102718858B (zh)	2011-03-29	2014-07-02	天津药物研究院	胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
CN102718868A (zh)	2011-03-30	2012-10-10	上海华谊生物技术有限公司	定点单取代聚乙二醇化Exendin类似物及其制备方法
US9790262B2 (en)	2011-04-05	2017-10-17	Longevity Biotech, Inc.	Compositions comprising glucagon analogs and methods of making and using the same
EP2696897A2 (en)	2011-04-11	2014-02-19	Yeda Research and Development Co. Ltd.	Albumin binding probes and drug conjugates thereof
WO2012150503A2 (en)	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
CN102766204B (zh)	2011-05-05	2014-10-15	天津药物研究院	胰高血糖素样肽-1突变体多肽及其制备方法和其应用
KR102497726B1 (ko)	2011-05-18	2023-02-07	메더리스 다이어비티즈, 엘엘씨	인슐린 저항성에 대한 개선된 펩티드 제약
US20140221282A1 (en)	2011-05-25	2014-08-07	Astrazeneca Pharmaceuticals Lp	Long duration dual hormone conjugates
UA113626C2 (xx)	2011-06-02	2017-02-27		Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN103764673A (zh)	2011-06-10	2014-04-30	北京韩美药品有限公司	葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用
CA2838503C (en)	2011-06-10	2020-02-18	Hanmi Science Co., Ltd.	Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2012174478A2 (en)	2011-06-17	2012-12-20	Halozyme, Inc.	Stable formulations of a hyaluronan-degrading enzyme
ES2710356T3 (es)	2011-06-17	2019-04-24	Hanmi Science Co Ltd	Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
MX2013015168A (es)	2011-06-22	2014-03-31	Univ Indiana Res & Tech Corp	Co-agonista del receptor de glucagon/glp-1.
ME02816B (me)	2011-06-22	2018-01-20	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
CN103906528A (zh)	2011-06-24	2014-07-02	安米林药品有限责任公司	用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
KR101357117B1 (ko)	2011-06-28	2014-02-06	비앤엘델리팜 주식회사	폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
US9944687B2 (en)	2011-07-04	2018-04-17	Imperial Innovations Limited	Compounds and their effects on feeding behaviour
US9382304B2 (en)	2011-07-08	2016-07-05	Amylin Pharmaceuticals, Llc	Engineered polypeptides having enhanced duration of action with reduced immunogenicity
CA2843586A1 (fr)	2011-08-10	2013-02-14	Adocia	Solution injectable d'au moins une insuline basale
US20130084277A1 (en)	2011-08-24	2013-04-04	Phasebio Pharmaceuticals, Inc.	Formulations of active agents for sustained release
WO2013029279A1 (zh)	2011-09-03	2013-03-07	深圳市健元医药科技有限公司	新的glp-ⅰ类似物及其制备方法和用途
MY167234A (en)	2011-09-23	2018-08-14	Novo Nordisk As	Novel glucagon analogues
US20130296236A1 (en)	2011-10-28	2013-11-07	Louise SILVESTRE	Treatment protocol of diabetes type 2
CN102363633B (zh)	2011-11-16	2013-11-20	天津拓飞生物科技有限公司	胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
HK1198810A1 (en)	2011-11-17	2015-06-12	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CA2852716C (en)	2011-11-29	2015-11-17	Jurox Pty Ltd	Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
PL2791160T3 (pl)	2011-12-16	2022-06-20	Modernatx, Inc.	Kompozycje zmodyfikowanego mrna
US9163227B2 (en)	2011-12-22	2015-10-20	Covx Technologies Ireland Limited	Anti-diabetic compounds
HK1200369A1 (en)	2011-12-23	2015-10-09	Zealand Pharma A/S	Glucagon analogues
CN104159570A (zh)	2011-12-29	2014-11-19	陈献	稳定的胰高血糖素纳米乳液
CN107583039A (zh)	2012-01-09	2018-01-16	阿道恰公司	Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
WO2013148966A1 (en)	2012-03-28	2013-10-03	Amylin Pharmaceuticals, Llc	Transmucosal delivery of engineered polypeptides
WO2013148871A1 (en)	2012-03-28	2013-10-03	Amylin Pharmaceuticals, Llc	Engineered polypeptides
AU2013243949A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of biologics and proteins associated with human disease
HK1206779A1 (en)	2012-04-02	2016-01-15	Modernatx, Inc.	Modified polynucleotides for the production of nuclear proteins
CN102649947A (zh)	2012-04-20	2012-08-29	无锡和邦生物科技有限公司	一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
WO2013163162A1 (en)	2012-04-24	2013-10-31	Amylin Pharmaceuticals, Llc	Site-specific enzymatic modification of exendins and analogs thereof
US20130289241A1 (en)	2012-04-26	2013-10-31	Shanghai Ambiopharm, Inc.	Method for preparing exenatide
WO2013182217A1 (en)	2012-04-27	2013-12-12	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
US8901484B2 (en)	2012-04-27	2014-12-02	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
CN104540850B (zh)	2012-05-03	2018-05-18	西兰制药公司	胰高血糖素样肽2(glp-2)类似物
WO2013164483A1 (en)	2012-05-03	2013-11-07	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
EP2664374A1 (en)	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
CN103421094A (zh)	2012-05-24	2013-12-04	上海医药工业研究院	一种具有epo类似活性的多肽化合物
US20150174209A1 (en)	2012-05-25	2015-06-25	Amylin Pharmaceuticals. Llc	Insulin-pramlintide compositions and methods for making and using them
MX2014015423A (es)	2012-06-14	2015-04-09	Sanofi Sa	Analogos de peptido de exedina-4.
CN104583232B (zh)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	展现gip受体活性的胰高血糖素类似物
DK2864350T3 (en)	2012-06-21	2018-05-28	Univ Indiana Res & Tech Corp	ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY
SG11201500218VA (en)	2012-07-12	2015-03-30	Mannkind Corp	Dry powder drug delivery systems and methods
IN2015DN00544A (es)	2012-07-23	2015-06-26	Zealand Pharma As
AR094821A1 (es)	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092862A1 (es)	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014027253A1 (en)	2012-08-14	2014-02-20	Wockhardt Limited	Pharmaceutical microparticulate compositions of polypeptides
EP2931300A1 (en)	2012-08-14	2015-10-21	Wockhardt Limited	Pharmaceutical microparticulate compositions of polypeptides
CN102816244A (zh)	2012-08-23	2012-12-12	无锡和邦生物科技有限公司	一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
CN102827270A (zh)	2012-09-13	2012-12-19	无锡和邦生物科技有限公司	一种聚乙二醇化艾塞那肽衍生物及其用途
WO2014041375A1 (en)	2012-09-17	2014-03-20	Imperial Innovations Limited	Peptide analogues of glucagon and glp1
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
WO2014049610A2 (en)	2012-09-26	2014-04-03	Cadila Healthcare Limited	Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MY197849A (en)	2012-11-06	2023-07-20	Hanmi Pharm Ind Co Ltd	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP6525456B2 (ja)	2012-11-20	2019-06-05	メデリスダイアビーティーズ，エルエルシー	インスリン抵抗性のための改善されたペプチド製剤
TWI617574B (zh)	2012-12-11	2018-03-11	梅迪繆思有限公司	用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
SG11201503526UA (en)	2012-12-21	2015-06-29	Sanofi Sa	Dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN103908657A (zh)	2012-12-31	2014-07-09	复旦大学附属华山医院	胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
US9714277B2 (en)	2013-03-14	2017-07-25	Medimmune Limited	Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
KR20150131213A (ko)	2013-03-14	2015-11-24	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	인슐린-인크레틴 접합체들
US20160058881A1 (en)	2013-03-15	2016-03-03	Indiana University Research And Technology Corporation	Prodrugs with prolonged action
WO2014170496A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2014227368A (ja)	2013-05-21	2014-12-08	国立大学法人帯広畜産大学	糖尿病および高血糖状態の処置のためのグルカゴンアナログ
CN103304660B (zh)	2013-07-12	2016-08-10	上海昂博生物技术有限公司	一种利拉鲁肽的合成方法
CN103405753B (zh)	2013-08-13	2016-05-11	上海仁会生物制药股份有限公司	稳定的促胰岛素分泌肽水针药物组合物
ES2688708T3 (es)	2013-10-17	2018-11-06	Zealand Pharma A/S	Análogos de glucagón acilados
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
US10131702B2 (en)	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086732A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
WO2015086731A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CN103665148B (zh)	2013-12-17	2016-05-11	中国药科大学	一种可口服给药的降糖多肽及其制法和用途
CN103980358B (zh)	2014-01-03	2016-08-31	杭州阿诺生物医药科技股份有限公司	一种制备利拉鲁肽的方法
SG11201604710XA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
GB201404002D0 (en)	2014-03-06	2014-04-23	Imp Innovations Ltd	Novel compounds
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (zh)	2014-09-23	2016-11-09	蒋先兴	胃泌酸调节素类似物
JP2017536343A (ja)	2014-10-10	2017-12-07	ノヴォノルディスクアー／エス	安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
MX382408B (es)	2014-10-24	2025-03-13	Merck Sharp & Dohme Llc	Coagonistas de los receptores de glucagón y de glp-1.
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198604A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物

2013
- 2013-12-19 SG SG11201503526UA patent/SG11201503526UA/en unknown
- 2013-12-19 AR ARP130104914A patent/AR094181A1/es unknown
- 2013-12-19 MA MA38276A patent/MA38276B1/fr unknown
- 2013-12-19 BR BR112015014510A patent/BR112015014510A2/pt not_active Application Discontinuation
- 2013-12-19 CA CA2895156A patent/CA2895156A1/en not_active Abandoned
- 2013-12-19 PT PT13810958T patent/PT2934567T/pt unknown
- 2013-12-19 CN CN201380066471.6A patent/CN104870009B/zh active Active
- 2013-12-19 HU HUE13811510A patent/HUE035803T2/en unknown
- 2013-12-19 EP EP13810957.4A patent/EP2934566B1/en active Active
- 2013-12-19 KR KR1020157015384A patent/KR20150096398A/ko not_active Withdrawn
- 2013-12-19 CA CA2895875A patent/CA2895875A1/en not_active Abandoned
- 2013-12-19 SG SG11201503576XA patent/SG11201503576XA/en unknown
- 2013-12-19 DK DK13810958.2T patent/DK2934567T3/en active
- 2013-12-19 AU AU2013366692A patent/AU2013366692B2/en not_active Ceased
- 2013-12-19 SG SG10201705097PA patent/SG10201705097PA/en unknown
- 2013-12-19 HR HRP20180092TT patent/HRP20180092T1/hr unknown
- 2013-12-19 EP EP13814892.9A patent/EP2934569A1/en not_active Withdrawn
- 2013-12-19 SI SI201331127T patent/SI2934567T1/sl unknown
- 2013-12-19 CN CN201380066991.7A patent/CN104902918A/zh active Pending
- 2013-12-19 MX MX2015008079A patent/MX362190B/es active IP Right Grant
- 2013-12-19 CA CA2895755A patent/CA2895755A1/en not_active Abandoned
- 2013-12-19 SG SG11201503524PA patent/SG11201503524PA/en unknown
- 2013-12-19 CA CA2894765A patent/CA2894765A1/en not_active Abandoned
- 2013-12-19 AU AU2013366691A patent/AU2013366691A1/en not_active Abandoned
- 2013-12-19 RU RU2015129815A patent/RU2652783C2/ru not_active IP Right Cessation
- 2013-12-19 EP EP13810958.2A patent/EP2934567B9/en active Active
- 2013-12-19 MX MX2015008099A patent/MX360317B/es active IP Right Grant
- 2013-12-19 MX MX2015008077A patent/MX2015008077A/es unknown
- 2013-12-19 WO PCT/EP2013/077307 patent/WO2014096145A1/en not_active Ceased
- 2013-12-19 ES ES13810958.2T patent/ES2688367T3/es active Active
- 2013-12-19 CN CN201380067043.5A patent/CN104902920A/zh active Pending
- 2013-12-19 PL PL13811510T patent/PL2934568T3/pl unknown
- 2013-12-19 MX MX2015008114A patent/MX2015008114A/es unknown
- 2013-12-19 BR BR112015014800A patent/BR112015014800A2/pt not_active Application Discontinuation
- 2013-12-19 RU RU2015129788A patent/RU2015129788A/ru not_active Application Discontinuation
- 2013-12-19 LT LTEP13811510.0T patent/LT2934568T/lt unknown
- 2013-12-19 EP EP18164271.1A patent/EP3400957A1/en not_active Withdrawn
- 2013-12-19 PE PE2015001035A patent/PE20151239A1/es unknown
- 2013-12-19 AR ARP130104911A patent/AR094178A1/es unknown
- 2013-12-19 HR HRP20181300TT patent/HRP20181300T1/hr unknown
- 2013-12-19 EA EA201591174A patent/EA031428B1/ru not_active IP Right Cessation
- 2013-12-19 JP JP2015548553A patent/JP2016503771A/ja not_active Abandoned
- 2013-12-19 AR ARP130104909A patent/AR099912A1/es unknown
- 2013-12-19 HU HUE13810958A patent/HUE038748T2/hu unknown
- 2013-12-19 PT PT138115100T patent/PT2934568T/pt unknown
- 2013-12-19 AR ARP130104913A patent/AR094180A1/es unknown
- 2013-12-19 EP EP13811510.0A patent/EP2934568B1/en active Active
- 2013-12-19 CN CN201380067038.4A patent/CN104902919B/zh not_active Expired - Fee Related
- 2013-12-19 LT LTEP13810958.2T patent/LT2934567T/lt unknown
- 2013-12-19 JP JP2015548552A patent/JP6391589B2/ja active Active
- 2013-12-19 SG SG11201504215PA patent/SG11201504215PA/en unknown
- 2013-12-19 HK HK15112143.4A patent/HK1211232A1/xx unknown
- 2013-12-19 BR BR112015013809A patent/BR112015013809A2/pt active Search and Examination
- 2013-12-19 RU RU2015129696A patent/RU2015129696A/ru not_active Application Discontinuation
- 2013-12-19 JP JP2015548554A patent/JP6408998B2/ja not_active Expired - Fee Related
- 2013-12-19 WO PCT/EP2013/077310 patent/WO2014096148A1/en not_active Ceased
- 2013-12-19 RS RS20180942A patent/RS57531B1/sr unknown
- 2013-12-19 ES ES13811510.0T patent/ES2653765T3/es active Active
- 2013-12-19 WO PCT/EP2013/077313 patent/WO2014096150A1/en not_active Ceased
- 2013-12-19 JP JP2015548550A patent/JP2016506401A/ja not_active Abandoned
- 2013-12-19 PL PL13810958T patent/PL2934567T3/pl unknown
- 2013-12-19 WO PCT/EP2013/077312 patent/WO2014096149A1/en not_active Ceased
- 2013-12-19 DK DK13811510.0T patent/DK2934568T3/en active
- 2013-12-19 UA UAA201507199A patent/UA116553C2/uk unknown
- 2013-12-19 HK HK16101474.5A patent/HK1213483A1/zh unknown
- 2013-12-19 HK HK15112142.5A patent/HK1211231A1/xx unknown
- 2013-12-19 AU AU2013360721A patent/AU2013360721A1/en not_active Abandoned
- 2013-12-19 KR KR1020157017458A patent/KR20150096684A/ko not_active Withdrawn
- 2013-12-19 KR KR1020157017459A patent/KR20150096433A/ko not_active Ceased
- 2013-12-19 AU AU2013366690A patent/AU2013366690B2/en not_active Ceased
- 2013-12-19 KR KR1020157018591A patent/KR20150099548A/ko not_active Withdrawn
- 2013-12-19 SI SI201330923T patent/SI2934568T1/en unknown
- 2013-12-20 US US14/136,061 patent/US9745360B2/en not_active Expired - Fee Related
- 2013-12-20 US US14/135,756 patent/US20140206608A1/en not_active Abandoned
- 2013-12-20 UY UY0001035231A patent/UY35231A/es not_active Application Discontinuation
- 2013-12-20 US US14/135,801 patent/US9670261B2/en active Active
- 2013-12-20 US US14/135,772 patent/US20140213513A1/en not_active Abandoned
- 2013-12-20 UY UY0001035232A patent/UY35232A/es not_active Application Discontinuation
- 2013-12-20 TW TW102147360A patent/TWI602828B/zh not_active IP Right Cessation
- 2013-12-20 UY UY0001035234A patent/UY35234A/es not_active Application Discontinuation
- 2013-12-20 UY UY0001035233A patent/UY35233A/es not_active Application Discontinuation
- 2013-12-20 TW TW102147363A patent/TWI600663B/zh not_active IP Right Cessation
- 2013-12-20 TW TW102147362A patent/TW201441252A/zh unknown
- 2013-12-20 TW TW102147359A patent/TW201441251A/zh unknown
2015
- 2015-05-04 IL IL238623A patent/IL238623A0/en unknown
- 2015-05-05 IL IL238650A patent/IL238650A0/en unknown
- 2015-05-07 IL IL238692A patent/IL238692A0/en unknown
- 2015-05-29 ZA ZA2015/03914A patent/ZA201503914B/en unknown
- 2015-05-31 IL IL239101A patent/IL239101A0/en unknown
- 2015-06-05 PH PH12015501291A patent/PH12015501291B1/en unknown
- 2015-06-18 DO DO2015000156A patent/DOP2015000156A/es unknown
- 2015-06-18 TN TNP2015000283A patent/TN2015000283A1/fr unknown
- 2015-06-18 CL CL2015001751A patent/CL2015001751A1/es unknown
- 2015-07-08 CR CR20150358A patent/CR20150358A/es unknown
- 2015-07-20 EC ECIEPI201531141A patent/ECSP15031141A/es unknown
2016
- 2016-07-22 AR ARP160102245A patent/AR105816A2/es unknown
- 2016-08-31 CL CL2016002182A patent/CL2016002182A1/es unknown
2017
- 2017-04-12 US US15/486,054 patent/US10253079B2/en active Active
2018
- 2018-01-17 CY CY20181100056T patent/CY1120030T1/el unknown
- 2018-08-09 CY CY20181100833T patent/CY1121153T1/el unknown

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Braga et al., "Making Crystals from Crystals: a green route to crystal engineering and polymorphism," Chem. Commun., 2005,pp 3635-3645 *
Seddon, K.R., "Pseudopolymorph: a polemic," Crystal Growth & Design, 2004, 4(6), pp 1087, web release date October 19,2004 *
Vippagunta et al. "Crystalline Solids," Advanced Drug Delivery Reviews, 2001,48, pp 3-26. *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
US10259885B2 (en)	2012-05-08	2019-04-16	Alderbio Holdings Llc	Anti-PCSK9 antibodies and use thereof
US9365632B2 (en)	2012-10-09	2016-06-14	Sanofi	Exendin-4 derivatives as dual GLP1/glucagon agonists
US10758592B2 (en)	2012-10-09	2020-09-01	Sanofi	Exendin-4 derivatives as dual GLP1/glucagon agonists
US9745360B2 (en)	2012-12-21	2017-08-29	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US10253079B2 (en)	2012-12-21	2019-04-09	Sanofi	Functionalized Exendin-4 derivatives
US11485753B2 (en)	2012-12-21	2022-11-01	Janssen Pharmaceutica Nv	Substituted nucleosides, nucleotides and analogs thereof
US12173025B2 (en)	2012-12-21	2024-12-24	Janssen Pharmaceuticals, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9670261B2 (en)	2012-12-21	2017-06-06	Sanofi	Functionalized exendin-4 derivatives
US9750788B2 (en)	2013-12-13	2017-09-05	Sanofi	Non-acylated exendin-4 peptide analogues
US9751926B2 (en)	2013-12-13	2017-09-05	Sanofi	Dual GLP-1/GIP receptor agonists
US9789165B2 (en)	2013-12-13	2017-10-17	Sanofi	Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9694053B2 (en)	2013-12-13	2017-07-04	Sanofi	Dual GLP-1/glucagon receptor agonists
US9771406B2 (en)	2014-04-07	2017-09-26	Sanofi	Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en)	2014-04-07	2017-10-03	Sanofi	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9758561B2 (en)	2014-04-07	2017-09-12	Sanofi	Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN114848799A (zh) *	2015-05-28	2022-08-05	免疫新炉有限公司	用于肌肉减少症治疗的包括胰高血糖素样肽-1受体激动剂的药物组合物
US10806797B2 (en)	2015-06-05	2020-10-20	Sanofi	Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
US9982029B2 (en)	2015-07-10	2018-05-29	Sanofi	Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10894076B2 (en)	2015-12-29	2021-01-19	Pegbio Co., Ltd.	Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof
US11214606B2 (en)	2019-08-16	2022-01-04	Applied Molecular Transport Inc.	Compositions, formulations and interleukin production and purification
US11466067B2 (en)	2019-08-16	2022-10-11	Applied Molecular Transport Inc.	Compositions, formulations and interleukin production and purification
US11479593B2 (en)	2019-08-16	2022-10-25	Applied Molecular Transport Inc.	Compositions, formulations and interleukin production and purification
US11160869B2 (en)	2019-08-16	2021-11-02	Applied Molecular Transport Inc.	Compositions, formulations and interleukin production and purification
US12215133B2 (en)	2021-03-25	2025-02-04	Brightgene Bio-Medical Technology Co., Ltd.	GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Also Published As

Publication number	Publication date
RS57531B1 (sr)	2018-10-31
EA031428B1 (ru)	2018-12-28
IL238692A0 (en)	2015-06-30
AU2013366692B2 (en)	2017-11-23
BR112015013809A2 (pt)	2017-11-14
CR20150358A (es)	2015-09-16
PH12015501291B1 (en)	2020-06-05
CN104870009A (zh)	2015-08-26
TW201441251A (zh)	2014-11-01
DOP2015000156A (es)	2015-08-31
EA201591174A1 (ru)	2016-03-31
CA2894765A1 (en)	2014-06-26
US10253079B2 (en)	2019-04-09
AU2013366690A1 (en)	2015-07-09
RU2015129815A (ru)	2017-01-27
DK2934568T3 (en)	2018-01-22
SG11201503524PA (en)	2015-06-29
TW201429985A (zh)	2014-08-01
SG10201705097PA (en)	2017-07-28
US20140221281A1 (en)	2014-08-07
MX2015008079A (es)	2015-10-30
PH12015501291A1 (en)	2015-08-24
ECSP15031141A (es)	2015-11-30
MA38276A1 (fr)	2017-06-30
JP2016503770A (ja)	2016-02-08
EP2934567A1 (en)	2015-10-28
SI2934568T1 (en)	2018-03-30
MX362190B (es)	2019-01-08
SI2934567T1 (sl)	2018-10-30
MX2015008114A (es)	2015-11-06
UY35233A (es)	2014-07-31
AR099912A1 (es)	2016-08-31
HK1211233A1 (en)	2016-05-20
PL2934568T3 (pl)	2018-03-30
UY35231A (es)	2014-07-31
EP2934568A1 (en)	2015-10-28
HK1211232A1 (en)	2016-05-20
HUE038748T2 (hu)	2018-11-28
PE20151239A1 (es)	2015-09-08
US20140213513A1 (en)	2014-07-31
US20140206609A1 (en)	2014-07-24
SG11201503576XA (en)	2015-06-29
CN104870009B (zh)	2021-05-18
CY1120030T1 (el)	2018-12-12
KR20150096433A (ko)	2015-08-24
KR20150096684A (ko)	2015-08-25
JP6391589B2 (ja)	2018-09-19
EP2934569A1 (en)	2015-10-28
LT2934567T (lt)	2018-09-10
ES2653765T3 (es)	2018-02-08
TWI600663B (zh)	2017-10-01
UY35234A (es)	2014-07-31
EP2934566B1 (en)	2017-06-21
AR094178A1 (es)	2015-07-15
CL2016002182A1 (es)	2018-01-12
TWI602828B (zh)	2017-10-21
BR112015014510A2 (pt)	2017-11-21
TW201441252A (zh)	2014-11-01
ZA201503914B (en)	2016-12-21
SG11201503526UA (en)	2015-06-29
MX2015008099A (es)	2016-04-25
RU2015129696A (ru)	2017-01-27
RU2015129788A (ru)	2017-01-30
EP2934567B9 (en)	2018-08-22
JP6408998B2 (ja)	2018-10-17
US20170216406A1 (en)	2017-08-03
EP3400957A1 (en)	2018-11-14
DK2934567T3 (en)	2018-08-13
UA116553C2 (uk)	2018-04-10
MA38276B1 (fr)	2018-03-30
TN2015000283A1 (fr)	2016-10-03
KR20150099548A (ko)	2015-08-31
US9670261B2 (en)	2017-06-06
EP2934568B1 (en)	2017-10-18
CL2015001751A1 (es)	2015-09-21
PL2934567T3 (pl)	2018-10-31
MX360317B (es)	2018-10-29
SG11201504215PA (en)	2015-06-29
ES2688367T3 (es)	2018-11-02
HRP20181300T1 (hr)	2018-10-05
IL238623A0 (en)	2015-06-30
AU2013366691A1 (en)	2015-07-09
AR105816A2 (es)	2017-11-15
US9745360B2 (en)	2017-08-29
AU2013360721A1 (en)	2015-07-09
KR20150096398A (ko)	2015-08-24
WO2014096145A1 (en)	2014-06-26
WO2014096149A1 (en)	2014-06-26
IL239101A0 (en)	2015-07-30
WO2014096150A1 (en)	2014-06-26
CN104902919A (zh)	2015-09-09
TW201443080A (zh)	2014-11-16
AU2013366692A1 (en)	2015-07-09
IL238650A0 (en)	2015-06-30
JP2016503772A (ja)	2016-02-08
CN104902919B (zh)	2018-11-20
EP2934567B1 (en)	2018-05-09
CN104902918A (zh)	2015-09-09
CY1121153T1 (el)	2020-05-29
EP2934566A1 (en)	2015-10-28
AR094180A1 (es)	2015-07-15
HK1213483A1 (zh)	2016-07-08
CA2895156A1 (en)	2014-06-26
PT2934567T (pt)	2018-10-01
HRP20180092T1 (hr)	2018-02-23
LT2934568T (lt)	2018-02-12
WO2014096148A1 (en)	2014-06-26
CN104902920A (zh)	2015-09-09
JP2016506401A (ja)	2016-03-03
BR112015014800A2 (pt)	2017-10-10
CA2895755A1 (en)	2014-06-26
CA2895875A1 (en)	2014-06-26
RU2652783C2 (ru)	2018-05-03
UY35232A (es)	2014-07-31
JP2016503771A (ja)	2016-02-08
AR094181A1 (es)	2015-07-15
PT2934568T (pt)	2018-01-04
HK1211231A1 (en)	2016-05-20
MX2015008077A (es)	2015-10-30
HUE035803T2 (en)	2018-05-28
AU2013366690B2 (en)	2018-02-08

Publication	Publication Date	Title
US10253079B2 (en)	2019-04-09	Functionalized Exendin-4 derivatives
US10758592B2 (en)	2020-09-01	Exendin-4 derivatives as dual GLP1/glucagon agonists
US9789165B2 (en)	2017-10-17	Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3080154B1 (en)	2018-02-07	Dual glp-1/gip receptor agonists
US9750788B2 (en)	2017-09-05	Non-acylated exendin-4 peptide analogues
US20150315260A1 (en)	2015-11-05	Exendin-4 derivatives as peptidic dual glp-1/glucagon receptor agonists
US20150322129A1 (en)	2015-11-12	Peptidic dual glp-1/glucagon receptor agonists derived from exendin-4
HK1262784A1 (en)	2020-01-17	Functionalized exendin-4 derivatives
HK1211233B (en)	2019-06-21	Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists

Legal Events

Date	Code	Title	Description
2014-05-13	AS	Assignment	Owner name: SANOFI, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAACK, TORSTEN;WAGNER, MICHAEL;HENKEL, BERND;AND OTHERS;REEL/FRAME:032875/0784 Effective date: 20131112
2017-09-06	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE
2017-09-19	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

Date

Code

Title

Description

2014-05-13

Assignment

Owner name: SANOFI, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAACK, TORSTEN;WAGNER, MICHAEL;HENKEL, BERND;AND OTHERS;REEL/FRAME:032875/0784

Effective date: 20131112

2017-09-06

STCB

Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

2017-09-19